var title_f18_47_19184="Hepatic metastases CT";
var content_f18_47_19184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A contrast-enhanced CT scan of the liver demonstrates multiple hypovascular metastases throughout all lobes of the liver. These lesions are typical of metastatic colon cancer. Ascites is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19184=[""].join("\n");
var outline_f18_47_19184=null;
var title_f18_47_19185="Synovial fluid analysis";
var content_f18_47_19185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Guide to synovial fluid analysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 599px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     * Adapted from Lipsky, P. Algorithms for the diagnosis and management of musculoskeletal complaints: A new tool for the primary-care provider, (See www.swmed.edu/home_pages/cme/endurmat/ lipsky/index.html).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19185=[""].join("\n");
var outline_f18_47_19185=null;
var title_f18_47_19186="Hailey-Hailey 1";
var content_f18_47_19186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hailey-Hailey disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical axillary plaque of Hailey-Hailey disease, showing superficial erosions and crusts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19186=[""].join("\n");
var outline_f18_47_19186=null;
var title_f18_47_19187="Hetastarch: Patient drug information";
var content_f18_47_19187=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hetastarch: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"     see \"Hetastarch: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/0/31748?source=see_link\">",
"     see \"Hetastarch: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hespan&reg;;",
"     </li>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10113100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691514",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low blood volume.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10113098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hetastarch or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2737529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, bleeding problems, high chloride levels, high sodium levels, very bad kidney disease, or a very weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10113246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low platelet count, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10113248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10113252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10113244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10113256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11377 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19187=[""].join("\n");
var outline_f18_47_19187=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179043\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113100\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113098\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113246\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113248\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113252\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113244\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113256\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=related_link\">",
"      Hetastarch: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/0/31748?source=related_link\">",
"      Hetastarch: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19188="Naphazoline (ophthalmic): Patient drug information";
var content_f18_47_19188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Naphazoline (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/60/15300?source=see_link\">",
"     see \"Naphazoline (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=see_link\">",
"     see \"Naphazoline (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9348239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Con&trade;;",
"     </li>",
"     <li>",
"      Clear eyes&reg; for Dry Eyes Plus ACR Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; for Dry Eyes plus Redness Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; Redness Relief [OTC];",
"     </li>",
"     <li>",
"      Clear eyes&reg; Seasonal Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9348240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naphcon Forte&reg;;",
"     </li>",
"     <li>",
"      Vasocon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naphazoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12265 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2EEB765D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19188=[""].join("\n");
var outline_f18_47_19188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024416\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024418\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024417\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024422\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024423\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024425\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024420\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024421\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024426\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024427\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/53/29523?source=related_link\">",
"      Naphazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=related_link\">",
"      Naphazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/57/10131?source=related_link\">",
"      Naphazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/60/15300?source=related_link\">",
"      Naphazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19189="Fusobacterium chorioamnionitis";
var content_f18_47_19189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusobacterium chorioamnionitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19189=[""].join("\n");
var outline_f18_47_19189=null;
var title_f18_47_19190="Pseudoephedrine: Drug information";
var content_f18_47_19190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/63/10229?source=see_link\">",
"    see \"Pseudoephedrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"    see \"Pseudoephedrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Children's Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Nexafed&reg; [OTC];",
"     </li>",
"     <li>",
"      Oranyl [OTC];",
"     </li>",
"     <li>",
"      Silfedrine Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Maximum Strength Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudo-Tab&reg; [OTC];",
"     </li>",
"     <li>",
"      SudoGest 12 Hour [OTC];",
"     </li>",
"     <li>",
"      SudoGest Children's [OTC] [DSC];",
"     </li>",
"     <li>",
"      SudoGest [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Decongestant;",
"     </li>",
"     <li>",
"      Benylin&reg; D for Infants;",
"     </li>",
"     <li>",
"      Contac&reg; Cold 12 Hour Relief Non Drowsy;",
"     </li>",
"     <li>",
"      Drixoral&reg; ND;",
"     </li>",
"     <li>",
"      Eltor&reg;;",
"     </li>",
"     <li>",
"      PMS-Pseudoephedrine;",
"     </li>",
"     <li>",
"      Pseudofrin;",
"     </li>",
"     <li>",
"      Robidrine&reg;;",
"     </li>",
"     <li>",
"      Sudafed&reg; Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     General dosing guidelines: Oral: Immediate release: 60 mg every 4-6 hours; Extended release: 120 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     240 mg every 24 hours; maximum: 240 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"      see \"Pseudoephedrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     General dosing guidelines: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-5 years: 15 mg every 4-6 hours; maximum: 60 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 30 mg every 4-6 hours; maximum: 120 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Use caution in this population; initiate using immediate release formulation: 30-60 mg every 6 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F215339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider reducing dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; 12 Hour: 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 30 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Nasal Decongestant: 30 mg/5 mL (118 mL) [contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silfedrine Children's: 15 mg/5 mL (118 mL, 237 mL) [ethanol free, sugar free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; Children's: 15 mg/5 mL (118 mL) [ethanol free, sugar free; contains menthol, sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 30 mg/5 mL (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest Children's: 15 mg/5 mL (118 mL [DSC]) [ethanol free, sugar free; contains sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nexafed&reg;: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oranyl: 30 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; Maximum Strength Nasal Decongestant: 30 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudo-Tab&reg;: 30 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest: 60 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; 24 Hour: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest 12 Hour: 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release products",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush extended release drug product, swallow whole. May administer with or without food. Sudafed&reg; 24 Hour tablet may not completely dissolve and appear in stool",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary symptomatic relief of nasal congestion due to common cold, upper respiratory allergies, and sinusitis; also promotes nasal or sinus drainage",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sudafed&reg; may be confused with sotalol, Sudafed PE&reg;, Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, cardiovascular collapse with hypotension, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, coordination impaired, dizziness, drowsiness, excitability, fatigue, hallucination, headache, insomnia, nervousness, neuritis, restlessness, seizure, transient stimulation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry throat, ischemic colitis, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Chest/throat tightness, dry nose, dyspnea, nasal congestion, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine or any component of the formulation; with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patient with renal impairment; consider dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with seizure disorder; may produce CNS stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium: Some products may contain sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur. Not for OTC use in children &lt;4 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F215328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Onset of effect may be delayed if pseudoephedrine is taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause hypertension).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of pseudoephedrine during the first trimester may be associated with a possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine's vasoconstrictive effects; additional studies are needed to define the magnitude of risk. Single doses of pseudoephedrine were not found to adversely affect the fetus during the third trimester of pregnancy (limited data); however, fetal tachycardia was noted in a case report following maternal use of an extended release product for multiple days. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral pseudoephedrine should be avoided during the first trimester.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11390950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pseudoephedrine is excreted into breast milk in concentrations that are ~4% of the weight adjusted maternal dose. The time to maximum milk concentration is ~1-2 hours after the maternal dose. Irritability has been reported in nursing infants (limited data; dose, duration, relationship to breast-feeding not provided). Milk production may be decreased in some women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F215320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (ElixSure Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (120 mL): $4.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Sudafed Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (118 mL): $4.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Pseudoephedrine HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (10): $2.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Sudafed 12 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (10): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Wal-phed 12 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (10): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Sudafed 24 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (10): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nexafed Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (24): $4.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pseudoephedrine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (24): $2.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $5.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Simply Stuffy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (24): $3.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sudafed Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (48): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SudoGest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $3.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $3.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wal-phed Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (48): $5.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F215321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acunaso (ZA);",
"     </li>",
"     <li>",
"      Afalpi Syrup (IL);",
"     </li>",
"     <li>",
"      Chemists' Own Sinus Relief (AU);",
"     </li>",
"     <li>",
"      Dexan (CN);",
"     </li>",
"     <li>",
"      Disofrol (SE);",
"     </li>",
"     <li>",
"      Disudrin (ID);",
"     </li>",
"     <li>",
"      Kopseu (KP);",
"     </li>",
"     <li>",
"      Logicin Plus (HK);",
"     </li>",
"     <li>",
"      Mex 24 (AR);",
"     </li>",
"     <li>",
"      Nasa-12 (LU);",
"     </li>",
"     <li>",
"      Otrinol (CH);",
"     </li>",
"     <li>",
"      Pseudono (TH);",
"     </li>",
"     <li>",
"      Rinafed (CR, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Rinomar (BE);",
"     </li>",
"     <li>",
"      Soludril Rhinites (LU);",
"     </li>",
"     <li>",
"      Subulin (TW);",
"     </li>",
"     <li>",
"      Sudafed (AE, AU, BB, BH, BM, BS, BZ, CY, EE, EG, FR, GB, GY, IE, IN, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MX, NL, OM, PL, PT, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Sudafed Sinus 12 Hour Relief (NZ);",
"     </li>",
"     <li>",
"      Sudomyl (NZ);",
"     </li>",
"     <li>",
"      Sudosian (TH);",
"     </li>",
"     <li>",
"      Tiptipot (IL);",
"     </li>",
"     <li>",
"      Vasocedine (BE);",
"     </li>",
"     <li>",
"      Vidadrine (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Decongestant: Oral: 30 minutes (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Decongestant: Oral: ~1-2 hours (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release tablet: 3-8 hours (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children: ~2.5 L/kg (Simons, 1996); Adults: 2.64-3.51 L/kg (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes n-demethylation to norpseudoephedrine (active) (Chua, 1989; Kanfer, 1993); Hepatic (&lt;1%) (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Varies by urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: ~3 hours (urine pH ~6.5) (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 9-16 hours (pH 8); 3-6 hours (pH 5) (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children (immediate release) ~2 hours (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults (immediate release): 1-3 hours (dose dependent) (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (43% to 96% as unchanged drug, 1% to 6% as active norpseudoephedrine); dependent on urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chua SS, Benrimoj SI, and Triggs EJ, &ldquo;Pharmacokinetics of Non-Prescription Sympathomimetic Agents,&rdquo;",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1989, 10(1):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/2647163/pubmed\" id=\"2647163\" target=\"_blank\">",
"        2647163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanfer I, Dowse R, and Vuma V, &ldquo;Pharmacokinetics of Oral Decongestants,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(6 Pt 2):116-28; discussion 143-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/7507589/pubmed\" id=\"7507589\" target=\"_blank\">",
"        7507589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pentel P, &ldquo;Toxicity of Over-the-Counter Stimulants,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1984, 252(14):1898-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/6471321/pubmed\" id=\"6471321\" target=\"_blank\">",
"        6471321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salmon J and Nicholson D, &ldquo;DIC and Rhabdomyolysis Following Pseudoephedrine Overdose,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1988, 6(5):545-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/3415750/pubmed\" id=\"3415750\" target=\"_blank\">",
"        3415750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Gu X, Watson WT, et al, &ldquo;Pharmacokinetics of the Orally Administered Decongestants Pseudoephedrine and Phenylpropanolamine in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(5):729-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/8917241/pubmed\" id=\"8917241\" target=\"_blank\">",
"        8917241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Werler MM,  &ldquo;Teratogen Update: Pseudoephedrine,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2006, 76(6):445-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19190/abstract-text/16933214/pubmed\" id=\"16933214\" target=\"_blank\">",
"        16933214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wezorek C, Dean B, and Krenzelok E, &ldquo;Pseudoephedrine: A Prospective Study to Establish a Toxic Dose in Children,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):554.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright S and Tomassoni A, &ldquo;Acute Myocardial Infarction Following Therapeutic Use of Pseudoephedrine,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:366.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9833 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19190=[""].join("\n");
var outline_f18_47_19190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215364\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215337\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215352\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215338\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215339\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215313\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803184\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215315\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215371\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215362\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215318\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215303\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299959\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215308\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215328\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630944\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215342\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390950\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215320\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422279\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215321\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215302\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215317\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/63/10229?source=related_link\">",
"      Pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=related_link\">",
"      Pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19191="Tenofovir: Drug information";
var content_f18_47_19191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenofovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/4/36933?source=see_link\">",
"    see \"Tenofovir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/52/36679?source=see_link\">",
"    see \"Tenofovir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatitis B infection:",
"     </b>",
"     Oral: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Tenofovir is recommended for first-line treatment of HBV (Lok, 2009). Concurrent use with adefovir and/or tenofovir combination products should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment duration (AASLD practice guidelines, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Decompensated liver disease: Lifelong treatment is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: 300 mg once daily (in combination with other antiretrovirals)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10485544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/52/36679?source=see_link\">",
"      see \"Tenofovir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;display:inline\">",
"     Children 2 to &lt;12 years: 8 mg/kg once daily (maximum: 300 mg once daily) (in combination with other antiretrovirals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosing recommendations based on body weight if using the",
"     <b>",
"      oral powder",
"     </b>",
"     :",
"     <b>",
"      Note:",
"     </b>",
"     One level scoop of powder = 40 mg tenofovir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10 to &lt;12 kg: 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     12 to &lt;14 kg: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     14 to &lt;17 kg: 120 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     17 to &lt;19 kg: 140 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     19 to &lt;22 kg: 160 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     22 to &lt;24 kg: 180 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     24 to &lt;27 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     27 to &lt;29 kg: 220 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     29 to &lt;32 kg: 240 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     32 to &lt;34 kg: 260 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     34 to &lt;35 kg: 280 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;35 kg: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosing recommendations based on body weight if using the",
"     <b>",
"      oral tablets",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     17 to &lt;22 kg: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     22 to &lt;28 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     28 to &lt;35 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;35 kg: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years (and &ge;35 kg) and Adolescents:  Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatitis B infection:",
"     </b>",
"     Oral: Children &ge;12 years (and &ge;35 kg) and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Use of powder formulation has not been evaluated in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 300 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 300 mg every 72-96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute without hemodialysis: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: 300 mg following dialysis every 7 days or after a total of  ~12 hours of dialysis  (usually once weekly assuming 3 dialysis sessions lasting about 4 hours each).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F729915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral, as disoproxil fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viread&reg;: 40 mg/g (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as disoproxil fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viread&reg;: 150 mg, 200 mg, 250 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be administered without regard to meals. Powder should be mixed with 2-4 ounces of soft food (applesauce, baby food, yogurt) and swallowed immediately (avoids bitter taste); do not mix in liquid (powder may float on top of the liquid even after stirring). Measure powder using only the supplied dosing scoop.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: Management of HIV infections in combination with at least two other antiretroviral agents in patients &ge;2 years of age; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease in patients &ge;12 years of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Management of HIV infections in combination with at least two other antiretroviral agents in patients &ge;12 years of age; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease in patients &ge;18 years of age",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies listed are treatment-emergent adverse effects noted at higher frequency than in the placebo group or comparator group. Only adverse events from treatment-naive studies which varied significantly were noted (eg, rash event). Patients treated for chronic hepatitis B had similar reactions and frequencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (3% to 4%; decompensated liver disease 18%), pain (7% to 13%), dizziness (3%; treatment na&iuml;ve 8%; decompensated liver disease 13%), depression (4% to 8%; treatment na&iuml;ve 9% to 11%), fever (2% to 4%; treatment na&iuml;ve 8%; decompensated liver disease 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash event (includes maculopapular, pustular, or vesiculobullous rash, pruritus or urticaria 5% to 7%; treatment na&iuml;ve 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (grades 3/4: 11%; treatment na&iuml;ve 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (4% to 7%; decompensated liver disease 22%), nausea (8% to 11%; decompensated liver disease 20%), diarrhea (11% to 16%), vomiting (4% to 7%; decompensated liver disease 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Creatine kinase increased (9% to 12%), weakness (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (9%), headache (5% to 8%), anxiety (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Serum amylase increased (grades 3/4: 4% to 7%; treatment na&iuml;ve 8% to 9%), anorexia (3% to 4%), dyspepsia (3% to 4%), flatulence (3% to 4%), weight loss (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Hematuria (grades 3/4: 3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 5%), alkaline phosphatase increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3% to 4%; treatment naive 9%), peripheral neuropathy (3% to 5%), myalgia (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (decompensated liver disease 9%), renal failure (decompensated liver disease 7%), glycosuria (grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (8%), sinusitis (8%), nasopharyngitis (5%), pneumonia (2% to 3%; treatment naive 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute tubular necrosis, allergic reaction, angioedema, bone mineral density decreased, dyspnea, Fanconi syndrome, hepatic steatosis, hepatitis, hypokalemia, hypophosphatemia, immune reconstitution syndrome, interstitial nephritis, lactic acidosis, muscle weakness, myopathy, nephrogenic diabetes insipidus, nephrotoxicity, osteomalacia, pancreatitis, polyuria, proteinuria, proximal renal tubulopathy, renal insufficiency, renal myopathy, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: There are no contraindications listed within the FDA-approved labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to tenofovir or any component of the formulation; concurrent use with fixed-dose combination products that contain tenofovir (Truvada&reg;, Atripla &reg;, Complera&reg;, or Stribild&trade;); concurrent use with adefovir (Hepsera&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Use has been associated with decreases in bone mineral density (~5% to 7% in adults) and osteomalacia. Decreases in bone mineral density have also been observed in pediatric clinical trials. Consider monitoring of bone density in adult and pediatric patients with a history of pathologic fractures or with other risk factors for bone loss or osteoporosis. Consider calcium and vitamin D supplementation for all patients; effect of supplementation has not been studied but may be beneficial. Long-term bone health and fracture risk unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with tenofovir and other nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy. Calculate creatinine clearance prior to initiation of therapy and monitor renal function (including recalculation of creatinine clearance and serum phosphorus) during therapy. Dosage adjustment required in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute. Use with caution in patients with low body weight, or concurrent medications which increase tenofovir levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation.",
"     </b>",
"     Monitor liver function several months after discontinuing treatment; reinitiation of antihepatitis B therapy may be required. Treatment of HBV in patients with unrecognized/untreated HIV may lead to HIV resistance; patients should be tested for presence of HIV infection prior to initiating therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. No dosage adjustment is required; limited studies indicate the pharmacokinetics of tenofovir are not altered in hepatic dysfunction. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Tenofovir is predominately eliminated renally. Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tenofovir combination products: Do not use concurrently with tenofovir combination products (ie, Atripla&reg;, Complera&trade;, Stribild&trade;, Truvada&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to a higher incidence of hepatic and/or renal impairment, use with caution in the elderly. Dosage adjustment based on renal function may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Decreases in bone mineral density may occur; long term effects are unknown. Skeletal growth (height) appears to be unaffected in tenofovir-treated children and adolescents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not use as monotherapy in treatment of HIV. Treatment of HIV in patients with unrecognized/untreated hepatitis B virus (HBV) may lead to rapid HBV resistance. Patients should be tested for presence of chronic hepatitis B infection prior to initiation of therapy. In patients coinfected with HIV and HBV, an appropriate antiretroviral combination should be selected due to HIV resistance potential.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Fatty meals may increase the bioavailability of tenofovir. Tenofovir may be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in rat and rabbit reproduction studies. Decreased fetal growth and reduced fetal bone porosity were observed in monkeys. Clinical studies in children have shown bone demineralization with chronic use. Tenofovir crosses the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Limited data indicate decreased maternal bioavailability during the third trimester. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Renal function should also be monitored. The DHHS Perinatal HIV Guidelines consider tenofovir to be an alternative NRTI in dual nucleoside combination regimens. The DHHS Perinatal HIV Guidelines consider emtricitabine plus tenofovir, or lamivudine plus tenofovir as recommended dual NRTI/NtRTI backbones for HIV/HBV coinfected pregnant women. Hepatitis B flare may occur if tenofovir is discontinued postpartum.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F225421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider calcium and vitamin D supplementation in patients with history of bone fracture or osteopenia.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Viread Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/g (60 g): $544.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Viread Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $925.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $925.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $925.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $998.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with HIV: CBC with differential, reticulocyte count, creatine kinase, CD4 count, HIV RNA plasma levels, serum phosphorus; serum creatinine (prior to initiation and as clinically indicated therapy, hepatic function tests, bone density (patients with a history of bone fracture or have risk factors for bone loss); testing for HBV is recommended prior to the initiation of antiretroviral therapy; weight (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with HBV: HIV status (prior to initiation of therapy); bone density (long-term), serum phosphorus; serum creatinine (prior to initiation and as clinically indicated therapy); bone density (patients with a history of bone fracture or have risk factors for bone loss); HBV DNA (every 3-6 months during therapy); HBeAg and anti-HBe; LFTs every 3 months during therapy and for several months following discontinuation of tenofovir; signs/symptoms of HBV relapse/exacerbation following discontinuation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with HIV and HBV coinfection should be monitored for several months following tenofovir discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F855142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ricovir (TH);",
"     </li>",
"     <li>",
"      Viread (AR, AT, AU, BE, BG, CH, CL, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, MT, MX, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tenofovir disoproxil fumarate (TDF) is an analog of adenosine 5'-monophosphate; it interferes with the HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication. TDF is first converted intracellularly by hydrolysis to tenofovir and subsequently phosphorylated to the active tenofovir diphosphate; nucleotide reverse transcriptase inhibitor. Tenofovir inhibits replication of HBV by inhibiting HBV polymerase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2-1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;7% to serum proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Tenofovir disoproxil fumarate (TDF) is converted intracellularly by hydrolysis (by non-CYP enzymes) to tenofovir, then phosphorylated to the active tenofovir diphosphate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~25% (fasting); increases ~40% with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Fasting: 36-84 minutes; With food: 96-144 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70% to 80%) via filtration and active secretion, primarily as unchanged tenofovir",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009. Available at file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/47/19191/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9895 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19191=[""].join("\n");
var outline_f18_47_19191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709065\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225434\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225454\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225437\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485544\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062229\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225438\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729915\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225413\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225411\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225452\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225416\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225400\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225430\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225406\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225420\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225442\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225421\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225422\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225419\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855142\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225399\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225415\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/4/36933?source=related_link\">",
"      Tenofovir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/52/36679?source=related_link\">",
"      Tenofovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19192="Disease associations of human herpesvirus 8 infection";
var content_f18_47_19192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disease associations of human herpesvirus 8 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Corey Casper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19192/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/47/19192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of Kaposi sarcoma (KS), a rare malignancy prior to the advent of the AIDS epidemic, suggested a link between the development of disease and a transmissible agent. In 1994, a novel gamma herpesvirus was subsequently identified in KS biopsies. After sequence analysis of the genome and characterization of the viral life cycle, this virus was subsequently named human herpesvirus 8 (HHV-8), or Kaposi sarcoma associated herpesvirus (KSHV).",
"   </p>",
"   <p>",
"    The first disease associated with HHV-8 infection was KS. However, it soon became appreciated that several other conditions, especially body cavity based lymphoma (also known as primary effusion lymphoma or PEL) and Castleman's disease, were also linked to this virus. Host factors influence disease expression, since HHV-8 seroprevalence is relatively common. The onset of disease typically occurs several years after acquisition of infection.",
"   </p>",
"   <p>",
"    The diseases that are or may be associated with HHV-8 infection will be reviewed here. The epidemiology, mode of transmission, diagnosis, and treatment of HHV-8 infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6743?source=see_link\">",
"     \"Diagnosis and antiviral therapy of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of primary infection with subsequent HHV-8 seroconversion have been described in children, men who have sex with men (MSM), and immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HHV-8 infection may be associated with fever and a maculopapular rash in immunocompetent children. Evidence of HHV-8 infection was determined by serology and polymerase chain reaction (PCR) of blood and saliva in a prospective study of 86 children who presented to an emergency department with a febrile syndrome of uncertain origin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/1\">",
"     1",
"    </a>",
"    ]. Thirty-six (42 percent) were seropositive; 14 of these patients had PCR evidence of HHV-8 DNA (mostly in saliva), but only six had evidence supporting primary HHV-8 infection.",
"   </p>",
"   <p>",
"    Five of these six children had a maculopapular rash, which first appeared on the face and spread gradually to the trunk and extremities. The median duration of the rash was six days (range three to eight days) and the median duration of fever was 10 days (range 2 to 14 days). HHV-8 seroconversion was documented in the three patients in whom convalescent sera were obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies of HIV-negative MSM identified new onset lymphadenopathy in association with HHV-8 seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A mild illness with fatigue, diarrhea, and localized rash was also described in five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among immunocompromised persons such as solid organ transplant recipients and HIV-infected individuals, fever, splenomegaly, lymphoid hyperplasia, pancytopenia, and occasionally rapid-onset KS have been described in association with apparent primary HHV-8 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In a case report, one HIV-infected patient experienced a severe illness characterized by marked fevers, hepatosplenomegaly, angiolymphoid hyperplasia, and transient KS during primary HHV-8 seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     KAPOSI SARCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The search for an infectious pathogen as the etiology for KS led to the original identification of HHV-8, which has been implicated as the causal agent. AIDS-related KS is discussed in detail elsewhere, while the following discussion will focus on KS occurring in other settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HHV-8 has been identified by PCR in all four types of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic &mdash; Classic KS is an indolent cutaneous proliferative disease, mainly affecting the lower extremities of elderly men of Mediterranean and Jewish origin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endemic &mdash; The endemic form of KS is found in all parts of equatorial Africa, affecting both children and adults, particularly in sub-Saharan Africa. It is not typically associated with immune deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/15\">",
"       15",
"      </a>",
"      ]. Endemic KS is frequently more aggressive than classic KS, and may be accompanied by dissemination to lymph nodes, bone, and skin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Organ transplant-associated &mdash; KS may occur after solid organ transplantation. Transplant-associated KS is similar to epidemic KS in its clinical manifestations and usually regresses with reduction in immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, the transplant itself may transmit HHV-8 infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Solid organ transplantation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link&amp;anchor=H19#H19\">",
"       \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\", section on 'Transmission'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidemic or&nbsp;AIDS-related &mdash; KS is the most common tumor arising in HIV-infected persons, and is an AIDS-defining illness in the Centers for Disease Control and Prevention (CDC) guidelines. In the United States, KS is over 20,000 times more common in persons with AIDS than in the general population and over 300 times more common in AIDS than in other immunosuppressed hosts, such as renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a landmark study, herpesvirus-like DNA sequences were identified in 20 of 21 patients with AIDS-associated KS, classic KS, and KS occurring in HIV-negative homosexuals; in contrast, these sequences were detected in only 1 of 21 skin biopsies from patients without KS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing demonstrates that infection with HHV-8 precedes and is predictive of the development of KS in certain populations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/13\">",
"     13",
"    </a>",
"    ]. However, while infection with HHV-8 is necessary for the development of KS, it alone may not be sufficient.",
"   </p>",
"   <p>",
"    Immunosuppression significantly increases the risk of developing KS from asymptomatic HHV-8 infection. KS is the most common tumor after solid organ transplantation in areas where HHV-8 is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/19\">",
"     19",
"    </a>",
"    ]. At the height of the AIDS epidemic, HIV-infected persons were at high risk of developing KS when compared with the general population (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast, discordance between HHV-8 seroprevalence and the development of KS has been observed in certain geographic areas. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 45,000 Ethiopian immigrants, none of the HIV-seronegative and &lt;1 percent of the HIV-seropositive patients developed KS despite HHV-8 seroprevalence rates of 39 and 57 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Thailand, HHV-8 seroprevalence was 24 percent across both HIV-positive and negative men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/21\">",
"       21",
"      </a>",
"      ], but the incidence of KS in AIDS patients was only 0.2 percent in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A low rate of progression of HHV-8-infected patients to classic KS has also been noted. This was demonstrated in a report from the Mediterranean in which the annual rate of development of classic KS was only 0.03 percent in infected men and 0.01 to 0.02 percent in infected women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible explanations for the geographic discrepancies in the incidence of KS following HHV-8 infection include differences in KS strains, genetic susceptibility to KS, or the absence of cofactors that play an important role in the pathogenesis of KS. The mechanisms by which HHV-8 might cause KS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five factors associated with a higher risk of developing KS are increasing anti-HHV-8 antibody titers, the presence of HHV-8 viremia, HIV seropositivity, reduced levels of neutralizing antibodies and poor cytotoxic T-cell responses to HHV-8. The data supporting these associations is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;KS is increasingly recognized as a complication of solid organ transplantation. In the United States, the incidence of KS after transplantation is estimated to be 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/17\">",
"     17",
"    </a>",
"    ] and KS represents 5.7 percent of malignancies after transplantation (excluding skin cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/24\">",
"     24",
"    </a>",
"    ]. The prevalence of KS was similar in a French registry of almost 8000 solid organ transplant recipients, although the rates were higher with liver transplants (1.24 percent) than with heart (0.41 percent) or kidney transplants (0.45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/25\">",
"     25",
"    </a>",
"    ]. In Saudi Arabia, KS is the most common cancer to occur after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the renal transplant population, the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-8 has been linked to the subsequent development of KS [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/19,26-28\">",
"       19,26-28",
"      </a>",
"      ]. In different studies from Europe, KS developed in as many as 15 to 28 percent of patients who were seropositive for HHV-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/26-28\">",
"       26-28",
"      </a>",
"      ] compared to less than 1 percent of patients who were initially seronegative [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although the KS risk is higher for those patients who are seropositive prior to transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/27,28\">",
"       27,28",
"      </a>",
"      ], HHV-8 seroconversion after renal transplant is also a risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transmission of HHV-8 infection from renal transplant donors to recipients has been documented. An assessment of serostatus before and after transplantation found seroconversion to occur in 12 to 24 percent of recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In five of eight transplant recipients who developed KS after receiving a kidney from HHV-8 seropositive donors, donor progenitor cells could be found within recipient KS tumor tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link&amp;anchor=H22#H22\">",
"       \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\", section on 'Solid organ transplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among transplant recipients who develop KS, regression often occurs following reduction of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/17,24,31\">",
"     17,24,31",
"    </a>",
"    ]. It has been estimated that approximately 40 percent of patients will respond to reduced immunosuppression alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A problem with this approach is that reduced immunosuppression carries the risk of acute rejection of the graft. A possible way to maintain graft function and treat the KS, at least with cutaneous KS, is to switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (rapamycin) has anti-tumor effects through the inhibition of the mammalian target of rapamycin (mTOR) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], as well as antiangiogenic effects mediated by impaired production of vascular endothelial growth factor (VEGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 15 kidney transplant recipients who developed cutaneous KS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy was discontinued and replaced with sirolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/35\">",
"     35",
"    </a>",
"    ]. Immunofluorescence staining of the KS biopsies demonstrated high levels of expression of VEGF within the lesions. Three months after initiation, all cutaneous KS lesions disappeared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intralesional therapy or adjuvant chemotherapy may be required in persons unresponsive to these conservative measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary effusion lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both non-Hodgkin's and Hodgkin lymphomas are important complications of longstanding HIV infection. Among these tumors, a specific subtype of non-Hodgkin lymphoma has been linked to HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. This B-cell lymphoma, which is characterized by its predilection for body cavities such as the peritoneal, pleural, and pericardial spaces, is known as primary effusion lymphoma or body cavity based lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Castleman's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Castleman's disease is an uncommon lymphoproliferative disorder, first described in 1956, which is associated with HHV-8 infection. Systemic features of Castleman's disease include fever, splenomegaly, hepatomegaly, and massive lymphadenopathy. Between 30 and 100 percent of Castleman's may be associated with HHV-8, including both HIV-negative and positive patients, and all variants of Castleman's (unicentric or multicentric disease and hyaline vascular or plasma cell variant) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H10#H10\">",
"     \"Castleman's disease\", section on 'Multicentric Castleman's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ASSOCIATIONS OF UNPROVEN SIGNIFICANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 DNA has been detected in biopsy tissue from a number of skin diseases other than Kaposi sarcoma. However, since HHV-8 can replicate in vascular endothelial cells, detecting HHV-8 DNA in biopsy tissue may not mean that the virus is responsible for the observed histopathology. The use of in situ hybridization can reveal specific areas within the biopsy where HHV-8 genes are expressed and can also be used to distinguish a true positive result from contamination when the PCR is positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49970309\">",
"    <span class=\"h3\">",
"     Angiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 infection has been associated with angiosarcoma in a number of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Each case has shown the presence of HHV-8 DNA in tumor tissue proliferation. Other studies have failed to find HHV-8 in angiosarcoma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/45-50\">",
"     45-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49970316\">",
"    <span class=\"h3\">",
"     Pemphigus vulgaris",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 DNA has sporadically been found in tissue from patients with pemphigus vulgaris [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. Almost all cases have occurred in the setting of immunosuppressive therapy, including one patient who developed KS at the site of a prior pemphigus lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/57\">",
"     57",
"    </a>",
"    ]. This has led some to speculate that HHV-8 may be implicated in the pathophysiology of pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49970323\">",
"    <span class=\"h3\">",
"     Large plaque parapsoriasis and mycosis fungoides",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described with angiosarcoma and pemphigus, HHV-8 DNA can occasionally be found in the peripheral blood and biopsy tissue of individuals with large plaque parapsoriasis (LPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/59\">",
"     59",
"    </a>",
"    ]. It is thought that LPP and mycosis fungoides (MF) represent different stages of the same underlying condition, but no evidence of HHV-8 infection in persons with MF had been found [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Highlighting the challenges with the use of PCR for establishing causal associations between the presence of HHV-8 DNA in tissue biopsy and the associated histopathology, a study of 53 patients with lymphoproliferative skin disorders found HHV-8 DNA by PCR in 7 of 8 LPP patients and 7 of 10 patients with MF, but none of 45 patients with LPP and MF had HHV-8 detected by in situ hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46535772\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have detected HHV-8 in the stromal dendritic cells from bone marrow biopsies of patients with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, this possible association has not been substantiated by further studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether HHV-8 exposure is associated with an increased risk of other tumors is unclear. No association was found in a large study from South Africa that examined the prevalence of HHV-8 seropositivity among a group of over 3000 patients with various cancer diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/10\">",
"     10",
"    </a>",
"    ]. HHV-8 seropositivity was only associated with a diagnosis of KS.",
"   </p>",
"   <p>",
"    However, a possible association with prostate cancer was suggested in a series that examined HHV-8 seroprevalence among 238 men with this tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 138 patients from",
"      <span class=\"nowrap\">",
"       Trinidad/Tobago,",
"      </span>",
"      HHV-8 seroprevalence was 40 percent compared with 23 percent in 140 age-matched controls.",
"     </li>",
"     <li>",
"      Of 100 patients from the United States, HHV-8 seroprevalence was 20 percent compared to 5 percent in 177 blood donors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Idiopathic pulmonary arterial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of lung biopsy specimens has raised a possible role for HHV-8 in the pathogenesis of idiopathic pulmonary arterial hypertension (IPAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/66\">",
"     66",
"    </a>",
"    ]. Evidence of HHV-8 virus by PCR and immunohistochemical assays was present in 10 of 16 patients with IPAH (62 percent) compared with none of 14 patients with secondary pulmonary hypertension. These findings do not distinguish a possible pathogenetic role for HHV-8 from the possibility that patients IPAH are coinfected with HHV-8 infection. Subsequent studies have failed to find an association between HHV-8 and pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report, HHV-8 DNA sequences were detected in lung biopsies in eight of eight sarcoid patients compared with 3 of 56 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/69\">",
"     69",
"    </a>",
"    ]. However, subsequent studies have not confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ketosis-prone diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infectious etiology for diabetes mellitus (DM) has been sought as a result of the observed ability of some viral infections to predispose to both insulin resistance and reductions in secreted insulin. An increasingly common presentation of DM in persons of African descent is the acute onset of ketosis, followed by reversible periods of decreased insulin secretion. In a study of 187 persons of African descent presenting for diabetes care in France, the seroprevalence of HHV-8 was 88 percent among the 81 individuals with ketosis-prone DM, compared with 15 percent among the 106 individuals with non-ketotic DM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19192/abstract/72\">",
"     72",
"    </a>",
"    ]. Twenty-two patients had plasma available from the time of first presentation, and 6 of 13 (46 percent) had HHV-8 DNA detectable in the ketotic group versus 0 of 9 in the non-ketotic group. Additional studies are needed to explore this preliminary finding in greater detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49969993\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epidemiology of Kaposi sarcoma (KS), a rare malignancy prior to the advent of the AIDS epidemic, suggested a link between the development of disease and a transmissible agent. In 1994, a novel gamma herpesvirus was identified in KS biopsies. After sequence analysis of the genome and characterization of the viral life cycle, this virus was named human herpesvirus 8 (HHV-8), or Kaposi sarcoma associated herpesvirus (KSHV). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 has been identified by the polymerase chain reaction in all four types of KS: classic, endemic, organ transplant-associated, and epidemic (AIDS-related) KS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Kaposi sarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While infection with HHV-8 is necessary for the development of KS, it alone may not be sufficient. Immunocompromise substantially increases the risk of developing KS from asymptomatic HHV-8 infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first disease associated with HHV-8 infection was KS. However, it soon became appreciated that several other conditions, especially body cavity based lymphoma (also known as primary effusion lymphoma or PEL) and Castleman's disease, were also linked to this virus. Host factors influence disease expression, since HHV-8 seroprevalence is relatively common. The onset of many HHV-8 associated diseases typically occurs several years after acquisition of infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute primary infection with subsequent HHV-8 seroconversion have been described in children, men who have sex with men (MSM), and immunocompromised hosts:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary HHV-8 infection may be associated with fever and a maculopapular rash in immunocompetent children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two studies of HIV-negative MSM identified new onset lymphadenopathy in association with HHV-8 seroconversion. A mild illness with fatigue, diarrhea, and localized rash has also been described in MSM. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Men who have sex with men'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among immunocompromised persons such as solid organ transplant recipients and HIV-infected individuals, fever, splenomegaly, lymphoid hyperplasia, pancytopenia, and occasionally rapid-onset KS may occur in association with apparent primary HHV-8 infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-8 DNA has also been detected in the blood or tissues of patients with a variety of diseases, including angiosarcoma, pemphigus vulgaris, multiple myeloma, idiopathic pulmonary arterial hypertension, and sarcoidosis. However, an etiologic role for HHV-8 has not been established for any of these diseases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Associations of unproven significance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/1\">",
"      Andreoni M, Sarmati L, Nicastri E, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002; 287:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/2\">",
"      Wang QJ, Jenkins FJ, Jacobson LP, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 2001; 97:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/3\">",
"      Casper C, Wald A, Pauk J, et al. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis 2002; 185:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/4\">",
"      Luppi M, Barozzi P, Santagostino G, et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000; 96:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/5\">",
"      Oksenhendler E, Cazals-Hatem D, Schulz TF, et al. Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N Engl J Med 1998; 338:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/6\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/7\">",
"      Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/8\">",
"      Chuck S, Grant RM, Katongole-Mbidde E, et al. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis 1996; 173:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/9\">",
"      Buonaguro FM, Tornesello ML, Beth-Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/10\">",
"      Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999; 340:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/11\">",
"      Purvis SF, Katongole-Mbidde E, Johnson JL, et al. High incidence of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda. J Infect Dis 1997; 175:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/12\">",
"      Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995; 345:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/13\">",
"      Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/14\">",
"      Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998; 12:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/15\">",
"      Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998; 78:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/16\">",
"      Taylor JF, Templeton AC, Vogel CL, et al. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer 1971; 8:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/17\">",
"      Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/18\">",
"      Gallant JE, Moore RD, Richman DD, et al. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. Arch Intern Med 1994; 154:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/19\">",
"      Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 1998; 65:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/20\">",
"      Grossman Z, Iscovich J, Schwartz F, et al. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc 2002; 77:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/21\">",
"      Chen N, Nelson KE, Jenkins FJ, et al. Seroprevalence of human herpesvirus 8 infection in Northern Thailand. Clin Infect Dis 2004; 39:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/22\">",
"      Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994--1998: regional variation and temporal trends. Clin Infect Dis 2001; 32:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/23\">",
"      Vitale F, Briffa DV, Whitby D, et al. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer 2001; 91:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/24\">",
"      Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/25\">",
"      Farge D. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993; 2:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/26\">",
"      Franc&egrave;s C, Mouquet C, Marcelin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 2000; 69:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/27\">",
"      Diociaiuti A, Nanni G, Cattani P, et al. HHV8 in renal transplant recipients. Transpl Int 2000; 13 Suppl 1:S410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/28\">",
"      Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/29\">",
"      Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/30\">",
"      Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/31\">",
"      Mendez JC, Paya CV. Kaposi's Sarcoma and Transplantation. Herpes 2000; 7:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/32\">",
"      Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/33\">",
"      Bhatt AP, Bhende PM, Sin SH, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010; 115:4455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/34\">",
"      Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/35\">",
"      Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/36\">",
"      Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/37\">",
"      Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/38\">",
"      Strauchen JA, Hauser AD, Burstein D, et al. Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated herpesvirus in an HIV-negative man with previous Kaposi sarcoma. Ann Intern Med 1996; 125:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/39\">",
"      Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996; 94:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/40\">",
"      Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/41\">",
"      Gyulai R, Kem&eacute;ny L, Kiss M, et al. Human herpesvirus 8 DNA sequences in angiosarcoma of the face. Br J Dermatol 1997; 137:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/42\">",
"      McDonagh DP, Liu J, Gaffey MJ, et al. Detection of Kaposi's sarcoma-associated herpesvirus-like DNA sequence in angiosarcoma. Am J Pathol 1996; 149:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/43\">",
"      Remick SC, Patnaik M, Ziran NM, et al. Human herpesvirus-8-associated disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors. Am J Med 2000; 108:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/44\">",
"      Steiner MC, Smith ME, Spittle MF. A patient with classical Kaposi's sarcoma and angiosarcoma: bad luck or a common aetiology? Clin Oncol (R Coll Radiol) 1997; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/45\">",
"      Lasota J, Miettinen M. Absence of Kaposi's sarcoma-associated virus (human herpesvirus-8) sequences in angiosarcoma. Virchows Arch 1999; 434:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/46\">",
"      Lin BT, Chen YY, Battifora H, Weiss LM. Absence of Kaposi's sarcoma-associated herpesvirus-like DNA sequences in malignant vascular tumors of the serous membranes. Mod Pathol 1996; 9:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/47\">",
"      Lebb&eacute; C, Tatoud R, Morel P, et al. Human herpesvirus 8 sequences are not detected in epithelial tumors from patients receiving transplants. Arch Dermatol 1997; 133:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/48\">",
"      Murakami M, Sugita Y, Ishii N, et al. Detection and sequence diversity of Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) DNA. Eur J Dermatol 1999; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/49\">",
"      Takata M, Hatta N, Takehara K, Fujiwara H. Absence of human herpesvirus-8 DNA in angiosarcomas and other skin tumours in immunocompetent patients, and in graft-versus-host disease in the immunosuppressed recipients of bone marrow transplants. Br J Dermatol 1997; 137:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/50\">",
"      Tomita Y, Naka N, Aozasa K, et al. Absence of Kaposi's-sarcoma-associated herpesvirus-like DNA sequences (KSHV) in angiosarcomas developing in body-cavity and other sites. Int J Cancer 1996; 66:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/51\">",
"      Memar OM, Rady PL, Goldblum RM, et al. Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol 1997; 133:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/52\">",
"      Jang HS, Oh CK, Lim JY, et al. Detection of human herpesvirus 8 DNA in pemphigus and chronic blistering skin diseases. J Korean Med Sci 2000; 15:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/53\">",
"      Bezold G, Sander CA, Flaig MJ, et al. Lack of detection of human herpesvirus (HHV)-8 DNA in lesional skin of German pemphigus vulgaris and pemphigus foliaceus patients. J Invest Dermatol 2000; 114:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/54\">",
"      Dupin N, Marcelin AG, Calvez V, Andr C. Absence of a link between human herpesvirus 8 and pemphigus. Br J Dermatol 1999; 141:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/55\">",
"      Cathomas G, Stalder A, Regamey N, et al. No evidence of HHV-8 infection in patients with pemphigus vulgaris/foliaceus. Arch Dermatol 1998; 134:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/56\">",
"      Cohen SS, Weinstein MD, Herndier BG, et al. No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. J Invest Dermatol 1998; 111:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/57\">",
"      Avalos-Peralta P, Herrera A, R&iacute;os-Mart&iacute;n JJ, et al. Localized Kaposi's sarcoma in a patient with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/58\">",
"      Pantanowitz L, Dezube BJ. Kaposi's sarcoma and pemphigus. J Eur Acad Dermatol Venereol 2007; 21:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/59\">",
"      Trento E, Castilletti C, Ferraro C, et al. Human herpesvirus 8 infection in patients with cutaneous lymphoproliferative diseases. Arch Dermatol 2005; 141:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/60\">",
"      Henghold WB 2nd, Purvis SF, Schaffer J, et al. No evidence of KSHV/HHV-8 in mycosis fungoides or associated disorders. J Invest Dermatol 1997; 108:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/61\">",
"      Nagore E, Ledesma E, Collado C, et al. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br J Dermatol 2000; 143:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/62\">",
"      Kreuter A, Bischoff S, Skrygan M, et al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides. Arch Dermatol 2008; 144:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/63\">",
"      Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/64\">",
"      Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997; 90:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/65\">",
"      Hoffman LJ, Bunker CH, Pellett PE, et al. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis 2004; 189:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/66\">",
"      Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/67\">",
"      Laney AS, De Marco T, Peters JS, et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 2005; 127:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/68\">",
"      Montani D, Marcelin AG, Sitbon O, et al. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005; 19:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/69\">",
"      Di Alberti L, Piattelli A, Artese L, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet 1997; 350:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/70\">",
"      B&eacute;lec L, Mohamed AS, Lechapt-Zalcman E, et al. Lack of HHV-8 DNA sequences in sarcoid tissues of French patients. Chest 1998; 114:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/71\">",
"      Maeda H, Niimi T, Sato S, et al. Human herpesvirus 8 is not associated with sarcoidosis in Japanese patients. Chest 2000; 118:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19192/abstract/72\">",
"      Sobngwi E, Choukem SP, Agbalika F, et al. Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. JAMA 2008; 299:2770.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8279 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19192=[""].join("\n");
var outline_f18_47_19192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49969993\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      KAPOSI SARCOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ASSOCIATIONS OF UNPROVEN SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Skin disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49970309\">",
"      - Angiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49970316\">",
"      - Pemphigus vulgaris",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49970323\">",
"      - Large plaque parapsoriasis and mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46535772\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Idiopathic pulmonary arterial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ketosis-prone diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49969993\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6743?source=related_link\">",
"      Diagnosis and antiviral therapy of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=related_link\">",
"      Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19193="Overview of pulmonary hypertension in adults";
var content_f18_47_19193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pulmonary hypertension in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Lewis J Rubin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19193/contributors\">",
"     William Hopkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19193/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/47/19193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure and secondary right ventricular failure (ie, cor pulmonale). It is a progressive, fatal disease if untreated, although the rate of progression is highly variable.",
"   </p>",
"   <p>",
"    The classification, epidemiology, etiologies, natural history, prognosis, and outcomes of PH are reviewed here. The pathogenesis, clinical features, diagnostic evaluation, diagnostic criteria, and treatment of PH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link\">",
"     \"Cor pulmonale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH was previously classified as primary pulmonary hypertension (now called idiopathic pulmonary arterial hypertension [IPAH]) or secondary PH. However, it became clear that some types of secondary PH closely resemble IPAH in their histopathology, natural history, and response to treatment. The World Health Organization (WHO), therefore, classified PH into five groups based upon mechanism (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Group 1 PAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pulmonary arterial hypertension (PAH)\". This group consists of sporadic IPAH, heritable IPAH, and PAH due to diseases that localize to small pulmonary muscular arterioles. These include connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, schistosomiasis, chronic hemolytic anemia, persistent pulmonary hypertension of the newborn, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12648?source=see_link\">",
"     \"Pulmonary hypertension associated with human immunodeficiency virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"     \"Portopulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=see_link\">",
"     \"Pulmonary veno-occlusive disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug- and toxin-induced PAH is also considered group 1 PAH. The following drugs are considered definite risk factors for PAH: aminorex, fenfluramine, dexfenfluramine, and toxic rapeseed oil [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, the following drugs are considered likely or possible risk factors for PAH: amphetamines, L-tryptophan, methamphetamines, cocaine, phenylpropanolamine, St. John's Wort, chemotherapeutic agents, and selective serotonin reuptake inhibitors.",
"   </p>",
"   <p>",
"    The hemodynamic parameters that define PAH are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H5397876#H5397876\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Pulmonary arterial hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Group 2 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pulmonary hypertension owing to left heart disease.\" PH due to systolic dysfunction, diastolic dysfunction, or valvular heart disease is included in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Group 3 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pulmonary hypertension owing to lung diseases or hypoxemia.\" This group includes PH due to chronic obstructive pulmonary disease, interstitial lung disease, pulmonary diseases with a mixed restrictive and obstructive pattern, sleep-disordered breathing, alveolar hypoventilation disorders, and causes of hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ]. It is usually severe lung disease that produces group 3 PH; in most circumstances, PH should not be attributed to lung disease if the pulmonary function tests are only mildly abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Group 4 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Chronic thromboembolic pulmonary hypertension.\" This group includes patients with PH due to thromboembolic occlusion of the proximal or distal pulmonary vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"     \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Group 5 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pulmonary hypertension with unclear multifactorial mechanisms.\" These patients have PH caused by hematologic disorders (eg, myeloproliferative disorders), systemic disorders (eg, sarcoidosis), metabolic disorders (eg, glycogen storage disease), or miscellaneous causes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5400621\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Pulmonary arterial hypertension&rdquo; (PAH) refers to group 1 PAH. &ldquo;Pulmonary hypertension&rdquo; (PH) refers to any of group 2 PH through group 5 PH. PH is also used when referring to all five groups collectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of group 1 PAH in the general population is estimated to be 5 to 15 cases per one million adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Similar estimates have not been performed for the other groups of PH, although the prevalence appears to vary widely among specific populations of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic sclerosis (SSc, formerly called scleroderma) &ndash; An observational study of 794 patients with SSc reported PAH in 12 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Portal hypertension &ndash; An observational study of 507 patients with portal hypertension reported PAH (ie, portopulmonary hypertension) in 2 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/6\">",
"       6",
"      </a>",
"      ], while a subsequent study reported PAH in about 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/7\">",
"       7",
"      </a>",
"      ]. The prevalence increases as the severity of the underlying cause of the portal hypertension (usually liver disease) worsens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"       \"Portopulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart disease &ndash; Congenital heart disease occurs in 8 out of every 1000 live births. Approximately 30 percent of children who do not have their congenital heart disease repaired will develop PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\", section on 'Evaluation for congenital heart disease related pulmonary arterial hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea (OSA) &ndash; A review of eight studies estimated that the prevalence of mild PH is 15 to 20 percent among patients with OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H5#H5\">",
"       \"Cardiovascular effects of obstructive sleep apnea\", section on 'Pulmonary hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    National surveillance data available was collected from patients with all groups of PH from 1980 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/10\">",
"     10",
"    </a>",
"    ]. It is unclear how changes in disease recognition, reporting, and treatment during this period impacted the results of this study.",
"   </p>",
"   <p>",
"    The death rate per annum increased from 5.2 to 5.4 per 100,000 population. The increase was greatest in African-Americans (4.6 to 7.3 per 100,000 population) and women (3.3 to 5.5 per 100,000 population). The death rate decreased in men (8.2 to 5.4 per 100,000 population) and remained stable in Caucasians (5.3 per 100,000 population). The most common cause of death was chronic lower respiratory disease from 1980 until 1999. Thereafter, PH itself was the most common cause of death.",
"   </p>",
"   <p>",
"    The hospitalization rate increased more than two-fold (40.8 to 90.1 per 100,000 population). The most common cause of hospitalization from 1980 until 1994 was chronic lower respiratory disease. Heart failure was the most common cause of hospitalization after 1994.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of PAH including IPAH (both sporadic and hereditary), drugs and toxins, connective tissue diseases, HIV infection, portal hypertension, and congenital heart disease. Similarly, there are many causes of PH including left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep related breathing disorders (eg, obstructive sleep apnea), and chronic thromboembolic pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary arterial hypertension (PAH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are etiologies of group 1 PAH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic pulmonary arterial hypertension (IPAH) &ndash; IPAH exists when an underlying cause of the PAH cannot be identified. It is usually sporadic, with only 6 to 10 percent of patients having hereditary disease in most series.",
"      <br/>",
"      <br/>",
"      Abnormal bone morphogenetic protein receptor type II (BMPR2) appears to play an important role in the pathogenesis of IPAH. In sporadic IPAH, up to 25 percent of patients have abnormal BMPR2 structure or function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In hereditary IPAH, the gene that encodes BMPR2 (IPAH1) appears to be transmitted as an autosomal dominant trait with incomplete penetrance [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/6,14-18\">",
"       6,14-18",
"      </a>",
"      ]. It has been estimated that up to 80 percent of hereditary IPAH is due to mutations in BMPR2 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Hereditary IPAH may be underdiagnosed. In one study, five apparently unrelated families (almost 400 individuals) were linked by pedigree analysis to a pair of common ancestors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/20\">",
"       20",
"      </a>",
"      ]. Among these families, 18 individuals were found to have hereditary IPAH, determined by the identification of identical BMP receptor type II mutations. Twelve of these subjects had been initially classified as having sporadic IPAH.",
"     </li>",
"     <li>",
"      Drugs and toxins &ndash; Appetite suppressants (eg, fenfluramine, dexfenfluramine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/23/8565?source=see_link\">",
"       diethylpropion",
"      </a>",
"      ) increase the risk of developing PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/11,21-24\">",
"       11,21-24",
"      </a>",
"      ]. In a case control study that compared 95 patients with PAH to 335 control patients, appetite suppressants increased the risk of PAH (odds ratio 6.3, 95% CI 3.0-13.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/21\">",
"       21",
"      </a>",
"      ]. The risk was particularly high when the appetite suppressants were used in the preceding year or for more than three months. Appetite suppressant use reported by patients with all types of PH is greater than that reported by the general population, suggesting that appetite suppressants may initiate PH in patients with underlying conditions that are associated with PH, or that obesity is associated with PH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/12\">",
"       12",
"      </a>",
"      ]. PAH has also been described in at least 70 patients following use of benfluorex, a drug marketed in Europe for treatment of diabetes and metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/25\">",
"       25",
"      </a>",
"      ]. Benfluorex shares an active metabolite with fenfluramine.",
"      <br/>",
"      <br/>",
"      Chronic use of cocaine or amphetamines, either inhaled or intravenous, has also been associated with PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/13,21,26,27\">",
"       13,21,26,27",
"      </a>",
"      ]. In one study, cocaine or amphetamine use increased the risk of developing PAH approximately three times [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/21\">",
"       21",
"      </a>",
"      ]. PAH has also been associated with recreational use of the designer amphetamine analog, 4-methyl-aminorex (ie, ice, euphoria, U-4-E-uh) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/28\">",
"       28",
"      </a>",
"      ], as well as methamphetamines, toxic rapeseed oil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Connective tissue diseases &ndash; Systemic sclerosis (SSc, also called scleroderma) causes PAH by obliteration of alveolar capillaries and narrowing of small arteries and arterioles due to pulmonary vascular disease and interstitial fibrosis. Isolated PAH appears to be more common in patients with limited SSc compared to patients with diffuse cutaneous SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Rheumatoid arthritis and systemic lupus erythematosus (SLE) can also lead to fibrous obliteration of the pulmonary vascular bed. There is a marked female predominance and a frequent association with the Raynaud phenomenon in patients with SLE who develop PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV) &ndash; PAH is a rare complication of HIV infection, occurring in approximately 1 out of every 200 HIV-infected patients (0.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. This is 6- to 12-times greater than the prevalence of PAH in individuals without HIV infection. The cause of HIV-related PAH is uncertain, but viral and host factors both likely play an important role. HIV-related PAH is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12648?source=see_link\">",
"       \"Pulmonary hypertension associated with human immunodeficiency virus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Portal hypertension &ndash; PAH associated with portal hypertension is referred to as portopulmonary hypertension. It is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"       \"Portopulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart disease &ndash; PAH due to congenital heart disease is due to pulmonary blood volume overload due to intracardiac shunting. Left to right shunts are most common, especially due to large (nonrestrictive) ventricular septal defects (VSD). PAH also occurs in patients with atrial septal defects (ASD). Noninvasive imaging, including transthoracic echocardiography, transesophageal echocardiography (TEE), and magnetic resonance imaging (MRI), can be used to characterize cardiac anatomy and function in patients with congenital heart defects (",
"      <a class=\"graphic graphic_movie graphicRef80448 \" href=\"UTD.htm?6/56/7040\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef57251 \" href=\"UTD.htm?17/39/18047\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77523 \" href=\"UTD.htm?36/39/37488\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension (PH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are etiologies of group 2, group 3, group 4, or group 5 PH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left heart disease &ndash; Left atrial hypertension requires an increased pulmonary artery systolic pressure to maintain an adequate driving force across the pulmonary vasculature. The degree of PH that results from any given level of left atrial hypertension varies greatly from individual to individual. This reflects the multiple impediments to normal pulmonary vascular flow that can exist, including reactive vasoconstriction, vascular remodeling, and left atrial hypertension itself.",
"      <br/>",
"      <br/>",
"      Causes of left atrial hypertension include left ventricular systolic or diastolic dysfunction, mitral and aortic valve disease, restrictive cardiomyopathy, constrictive pericarditis, and left atrial myxoma.",
"      <br/>",
"      <br/>",
"      Patients with left ventricular systolic dysfunction commonly have PH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. As an example, in a study of 108 patients with dilated cardiomyopathy, 26 percent had an estimated pulmonary artery systolic pressure above 40 mmHg, as determined by echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/36\">",
"       36",
"      </a>",
"      ]. This was associated with a greater likelihood of death or hospitalizations (89 versus 32 percent). Multiple factors contribute to cardiomyopathy-associated PH, including chronic pulmonary venous congestion, recurrent transient hypoxemia, and sleep-disordered breathing [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/38\">",
"       38",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Left ventricular diastolic dysfunction is also associated with PH. As an example, in an observational study of 244 patients with heart failure due to diastolic dysfunction, 83 percent had an estimated pulmonary artery systolic pressure &gt;35 mmHg as determined by Doppler echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/39\">",
"       39",
"      </a>",
"      ]. A high estimated pulmonary arterial systolic pressure predicted mortality in the study (unadjusted hazard ratio of 1.3 per 10 mmHg).",
"      <br/>",
"      <br/>",
"      The importance of mitral regurgitation as a cause of PH was shown in a study of 41 patients with isolated severe mitral regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/40\">",
"       40",
"      </a>",
"      ]. PH was identified in 76 percent of patients, of which 17 percent had a pulmonary artery systolic pressure greater than 70 mmHg.",
"     </li>",
"     <li>",
"      Chronic Obstructive Pulmonary Disease (COPD) &ndash; PH is a common complication of COPD with a significant impact on outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. One study reported a five-year survival rate &lt;10 percent among patients with COPD and a mean pulmonary arterial pressure &gt;45 mmHg, compared to a five-year survival rate &gt;90 percent among patients with COPD and a pulmonary arterial pressure &lt;25 mmHg (",
"      <a class=\"graphic graphic_figure graphicRef81545 \" href=\"UTD.htm?37/27/38333\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/43\">",
"       43",
"      </a>",
"      ]. The prevalence of PH in patients with COPD is more strongly associated with hypoxemia than symptoms or abnormal lung function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial lung disease (ILD) &ndash; ILD-related PH can exist when ILD is mild, but it is more common when hypoxemia and severe pulmonary dysfunction exist. In a prospective cohort study of 212 patients with ILD, PH was detected in 14 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/44\">",
"       44",
"      </a>",
"      ]. ILD-related PH is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link\">",
"       \"Pulmonary hypertension associated with interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep related breathing disorders &ndash; Obstructive sleep apnea (OSA) is the sleep related breathing disorder that is most often associated with PH. Untreated OSA alone is associated with only mild PH. However, it may be associated with significant PH when combined with obesity hypoventilation syndrome or another cause of hypoxemia. These patients have a significant risk of mortality due to progressive PH, cor pulmonale, or arrhythmias, although the magnitude of the risk is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H5#H5\">",
"       \"Cardiovascular effects of obstructive sleep apnea\", section on 'Pulmonary hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic thromboembolic disease &ndash; Organized proximal pulmonary emboli may cause severe PH in a small number of patients. The initial embolic episodes are often asymptomatic and the resting arterial oxygen level may be normal; however, virtually all patients demonstrate oxyhemoglobin desaturation with exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"       \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pulmonary angiography is unnecessary if a ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      scan is normal because a normal",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      scan accurately excludes thromboembolic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. When thromboembolic disease exists, however, pulmonary angiography is necessary to define the extent of disease and potential operability because perfusion scans tend to underestimate the extent of proximal embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PH is complex and just beginning to be elucidated. It is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of PH may be difficult to recognize because they are nonspecific. This is particularly true if the PH is caused by an underlying condition, since the clinical manifestations of PH are often obscured by the underlying disease. The clinical presentation, symptoms, and signs of PH are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that more than 20 percent of patients have symptoms of PH for longer than two years before the PH is recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/53\">",
"     53",
"    </a>",
"    ]. This delay is particularly prevalent among patients younger than 36 years and patients with chronic obstructive pulmonary disease or obstructive sleep apnea, probably because the symptoms are more likely to be attributed to other causes in such patients. Once a patient is suspected of having PH, extensive diagnostic testing is generally performed, which is aimed at confirming its presence, measuring its severity, and identifying its cause. The diagnostic evaluation, diagnostic criteria, and differential diagnosis of PH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH is a progressive, fatal condition if untreated. However, the rate of progression is highly variable and depends upon the type and severity of the PH. This has been shown in patients with PAH; patients with PH have not been studied, but there are no reasons to expect that PH is different than PAH in this regard.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type of PAH &ndash; Symptomatic patients with IPAH who do not receive treatment have a median survival of approximately three years. Symptomatic patients with PAH associated with another disease (eg, liver disease, systemic sclerosis [also called scleroderma]) generally have a worse prognosis; an exception is patients with PAH associated with Eisenmenger syndrome, who tend to have a better prognosis than patients with IPAH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/54-56\">",
"       54-56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severity of PAH &ndash; Patients with severe PAH or right heart failure (ie, cor pulmonale) die sooner without treatment (usually within one year) than patients with mild PAH or no right heart failure. As an example, patients with IPAH and a mean right atrial pressure &ge;20 mmHg have a median survival of approximately one month [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11244031\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one-year survival of patients with newly diagnosed group 1 PAH can be predicted using a risk score derived from the Registry to Evaluate Early and Long-term PAH Disease Management (ie, the REVEAL registry). This risk score was validated by a prospective cohort study of 504 patients with a mean 6MWD of 308 m and 61.5 percent classified as WHO functional class III (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"UTD.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ), which found that a risk score of 1 to 7, 8, 9, 10 to 11, and &ge;12 correlated with one-year survival of 95, 92, 89, 72, and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk score is calculated by adding six to the sum of the following (",
"    <a class=\"graphic graphic_figure graphicRef85543 \" href=\"UTD.htm?3/28/3530\">",
"     figure 2",
"    </a>",
"    ): connective tissue disease-associated PAH (+1 point), portopulmonary hypertension (+2 points), familial PAH (+2 points), renal insufficiency (+1 point), male older than 60 years (+2 points), WHO functional class I (-2 points), WHO functional class III (+1 point), WHO functional class IV (+2 points), systolic blood pressure &lt;110 mmHg (+1 point), heart rate &gt;92 bpm (+1 point), 6MWD &ge;440 m (-1 point), 6MWD &lt;165 m (+1 point), brain natriuretic peptide &lt;50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (-2 points), brain natriuretic peptide &gt;180",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (+1 point), pericardial effusion (+1 point), percent predicted DLCO &ge;80 (-1 point), percent predicted DLCO &le;32 (+1 point), mean right atrial pressure &gt;20 mmHg (+1 point), and pulmonary vascular resistance &gt;32 Wood units (+2 points).",
"   </p>",
"   <p>",
"    Another study that used data from the REVEAL registry reported that patients with PAH had one-, three-, five-, and seven-year survival rates of 85, 68, 57, and 49 percent, respectively, from the time of diagnostic right heart catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/58\">",
"     58",
"    </a>",
"    ]. A registry in the United Kingdom and Ireland of patients with PAH newly diagnosed between 2001 and 2009 found different survivals based on age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/4\">",
"     4",
"    </a>",
"    ]. Individuals over age 50 had one-, three-, five-, and seven-year survival rates of 90, 76, 57, and 44 percent, respectively, while those aged 50 or younger had survival rates of 95, 91, 87, and 75 percent, respectively.",
"   </p>",
"   <p>",
"    The contribution of being male toward the risk of death among individuals older than 60 years was confirmed in a separate study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/59\">",
"     59",
"    </a>",
"    ]. The study used data from the REVEAL registry and found that men had lower two-year survival than women among individuals with PAH who were older than 60 years (64 versus 78 percent, hazard ratio 1.67, 95% CI 1.28-2.17). In contrast, there was no difference in survival among men and women with PAH who were 60 years or younger (84 versus 86 percent).",
"   </p>",
"   <p>",
"    Other factors that may indicate a poor prognosis include an age at presentation &gt;45 years, World Health Organization (WHO) functional class III or IV (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"UTD.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ), failure to improve to a lower WHO functional class during treatment, pericardial effusion, large right atrial size, elevated right atrial pressure, septal shift during diastole, decreased pulmonary arterial capacitance (ie, the stroke volume divided by the pulmonary arterial pulse pressure), increased N-terminal pro-brain natriuretic peptide level (NT-pro-BNP), a prolonged QRS duration on an electrocardiogram, and possibly hypocapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/60-67\">",
"     60-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PAH who experience cardiac arrest rarely survive. In a retrospective study of more than 3000 patients with PAH who required cardiopulmonary resuscitation (CPR), only 6 percent survived for 90 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to realize that the prognostic factors described above are evaluated when PAH is newly diagnosed. Many may not be reliable for ongoing assessment of prognosis during routine follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early treatment of PH is generally suggested because advanced disease may be less responsive to therapy. The treatment of PH is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PH improves hemodynamic measures, WHO functional class, and the six-minute walking test distance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. It also appears to improve survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous uncontrolled trials and one controlled trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      therapy have demonstrated improved survival compared with historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/60,72-74\">",
"       60,72-74",
"      </a>",
"      ]. As an example, one trial demonstrated that survival among patients receiving epoprostenol was better than historical controls at one year (85 versus 58 percent), three years (63 versus 33 percent), and five years (55 versus 28 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 21 randomized trials (3140 patients) found that therapy with a prostanoid, an endothelin receptor antagonist, or a phosphodiesterase-5 inhibitor improves mortality compared to controls (1.5 versus 3.8 percent, RR 0.57, 95% CI 0.35 - 0.92) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19193/abstract/70\">",
"       70",
"      </a>",
"      ]. The average duration of the trials was 14 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=see_link\">",
"       \"Patient information: Pulmonary hypertension in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension is characterized by elevated pulmonary arterial pressure. The World Health Organization (WHO) classifies pulmonary hypertension into five groups, as shown in the table (",
"      <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      &ldquo;Pulmonary arterial hypertension&rdquo; (PAH) describes group 1 PAH, while &ldquo;pulmonary hypertension&rdquo; (PH) describes group 2 PH through group 5 PH. PH is also used to refer to all five groups collectively. (See",
"      <a class=\"local\" href=\"#H5400621\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many causes of PAH including drugs and toxins, connective tissue diseases, human immunodeficiency virus (HIV) infection, portal hypertension, and congenital heart disease. PAH can also be idiopathic. Similarly, there are many causes of PH including left heart disease, chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep related breathing disorders (eg, obstructive sleep apnea), and chronic thromboembolic pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PH is a progressive, fatal disease if untreated. However, the rate of progression is highly variable and depends upon the type and severity of the PH. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The one-year survival of patients newly diagnosed with group 1 PAH can be predicted using a risk score derived from the Registry to Evaluate Early and Long-term PAH Disease Management (ie, the REVEAL registry). (See",
"      <a class=\"local\" href=\"#H11244031\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy improves exercise capacity and functional class. It may also improve mortality, but this is less well established. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis, clinical features, diagnostic evaluation, diagnostic criteria, and treatment of PH are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"       \"Pathogenesis of pulmonary hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"       \"Treatment of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rich S (ed). Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, September 6-10, 1998, co-sponsored by The World Health Organization.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/2\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/3\">",
"      Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/4\">",
"      Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/5\">",
"      Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/6\">",
"      Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/7\">",
"      Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006; 44:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/8\">",
"      Friedman WF. Proceedings of National Heart, Lung, and Blood Institute pediatric cardiology workshop: pulmonary hypertension. Pediatr Res 1986; 20:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/9\">",
"      Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996; 9:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/10\">",
"      Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance--United States, 1980-2002. MMWR Surveill Summ 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/11\">",
"      Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003; 22:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/12\">",
"      Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/13\">",
"      Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of \"crank\" methamphetamine. Chest 1993; 104:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/14\">",
"      Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984; 129:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/15\">",
"      Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/16\">",
"      Deng Z, Haghighi F, Helleby L, et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 2000; 161:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/17\">",
"      Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/18\">",
"      International PPH Consortium, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/19\">",
"      Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ 2011; 1:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/20\">",
"      Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/21\">",
"      Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/22\">",
"      Voelkel NF, Clarke WR, Higenbottam T. Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned? Am J Respir Crit Care Med 1997; 155:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/23\">",
"      Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/24\">",
"      Delcroix M, Kurz X, Walckiers D, et al. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 1998; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/25\">",
"      Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/26\">",
"      Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest 1995; 108:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/27\">",
"      Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/28\">",
"      Gaine SP, Rubin LJ, Kmetzo JJ, et al. Recreational use of aminorex and pulmonary hypertension. Chest 2000; 118:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/29\">",
"      Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/30\">",
"      Alvarez PA, Saad AK, Flagel S, et al. Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. Cardiovasc Toxicol 2012; 12:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/31\">",
"      Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/32\">",
"      Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/33\">",
"      Himelman RB, Dohrmann M, Goodman P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/34\">",
"      Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/35\">",
"      Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/36\">",
"      Abramson, SV, Burke, JF, Kelly, JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992; 116:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/37\">",
"      Shah RV, Semigran MJ. Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management. Curr Heart Fail Rep 2008; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/38\">",
"      Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997; 29:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/39\">",
"      Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/40\">",
"      Alexopoulos D, Lazzam C, Borrico S, et al. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J Am Coll Cardiol 1989; 14:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/41\">",
"      Barber&agrave; JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/42\">",
"      Dallari R, Barozzi G, Pinelli G, et al. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration 1994; 61:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/43\">",
"      Bishop JM. Role of hypoxia in the pulmonary hypertension of chronic bronchitis and emphysema. Scand J Respir Dis Suppl 1971; 77:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/44\">",
"      Andersen CU, Mellemkj&aelig;r S, Hilberg O, et al. Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. Respir Med 2012; 106:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/45\">",
"      Partinen M, Guilleminault C. Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea patients. Chest 1990; 97:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/46\">",
"      Bady E, Achkar A, Pascal S, et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000; 55:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/47\">",
"      Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/48\">",
"      Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/49\">",
"      Moser KM, Fedullo PF, Finkbeiner WE, Golden J. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/50\">",
"      Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/51\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/52\">",
"      Ryan KL, Fedullo PF, Davis GB, et al. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. Chest 1988; 93:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/53\">",
"      Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011; 140:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/54\">",
"      Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/55\">",
"      Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/56\">",
"      D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/57\">",
"      Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/58\">",
"      Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/59\">",
"      Shapiro S, Traiger GL, Turner M, et al. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012; 141:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/60\">",
"      Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/61\">",
"      Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/62\">",
"      Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/63\">",
"      Mahapatra S, Nishimura RA, Sorajja P, et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/64\">",
"      Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/65\">",
"      Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007; 29:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/66\">",
"      Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/67\">",
"      Sun PY, Jiang X, Gomberg-Maitland M, et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest 2012; 141:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/68\">",
"      Hoeper MM, Gali&eacute; N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/69\">",
"      Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/70\">",
"      Gali&egrave; N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/71\">",
"      Rich S. The value of approved therapies for pulmonary arterial hypertension. Am Heart J 2007; 153:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/72\">",
"      Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/73\">",
"      McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19193/abstract/74\">",
"      Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8257 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-C796279318-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19193=[""].join("\n");
var outline_f18_47_19193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Group 1 PAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Group 2 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Group 3 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Group 4 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Group 5 PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5400621\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary arterial hypertension (PAH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary hypertension (PH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11244031\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8257|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/39/37488\" title=\"diagnostic image 1\">",
"      Ventricular septal defect MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8257|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/27/38333\" title=\"figure 1\">",
"      PA pressure and survival COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/28/3530\" title=\"figure 2\">",
"      PAH prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8257|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/56/7040\" title=\"movie 1\">",
"      TTE two ASDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/39/18047\" title=\"movie 2\">",
"      VSD small four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/47/25339\" title=\"table 2\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=related_link\">",
"      Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=related_link\">",
"      Patient information: Pulmonary hypertension in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12648?source=related_link\">",
"      Pulmonary hypertension associated with human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19194="Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy";
var content_f18_47_19194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19194/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19194/contributors\">",
"     M Elizabeth H Hammond, MD, FCAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19194/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/47/19194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/47/19194/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/47/19194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of steroid hormone receptors to the biology of breast cancer was recognized over 40 years ago, when it was observed that radiolabeled estrogens concentrated preferentially in the estrogen-influenced target organs of both animal and human breast cancers. These findings gave rise to the concept of an estrogen receptor (ER). It has since become clear that human breast cancers are dependent upon estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone for growth and that this effect is mediated through ERs and progesterone receptors (PRs). Not surprisingly, ER and PR are both overexpressed in malignant breast tissue.",
"   </p>",
"   <p>",
"    New insights into hormone receptor biology and the increasing array of proteins that can modify their function have already translated into better therapies for breast cancer. As an example, a number of drugs that interact with the receptor, called selective estrogen receptor modulators (SERMS), are approved for the treatment and prevention of breast cancer. At the same time, improved methods for assaying receptor proteins have led to less expensive and simpler measurements of ER and PR. Unfortunately, however, these methods have been fraught with variation that has resulted in inaccurate test results. Since these tests guide the use of endocrine therapy in patients with breast cancer, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) convened a panel to address causes of variation related to measurement of ER and PR by immunohistochemistry (IHC) in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we review the clinical utility of hormone receptor testing in breast cancer and the guideline recommendations published in 2010 for measurement of ER and PR in tissue samples by IHC. An overview of ER biology, the mechanism of action of SERMs at the level of the hormone receptor, the use of endocrine therapy for adjuvant treatment of early stage breast cancer and for treatment of metastatic disease, and an overview of prognostic factors for patients with breast cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link&amp;anchor=H2#H2\">",
"     \"Molecular biology and physiology of estrogen action\", section on 'Estrogen receptors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTROGEN AND PROGESTERONE RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER and PR are both members of the nuclear hormone receptor superfamily that includes the androgen and retinoid receptors. These receptors are located in the cytosol of target cells and operate as ligand-dependent transcription factors. Attachment of a lipid-soluble hormone to the ligand-binding domain results in unmasking of the DNA-binding sites on the receptor, followed by migration into the nucleus, and binding to specific hormone-responsive elements near the genes that are responsible for the physiologic actions of the hormone.",
"   </p>",
"   <p>",
"    Subsequent steps include transcription of messenger RNA and ribosomal RNA, and the eventual synthesis of new proteins. Two isoforms of the ER have been identified: ER-alpha and ER-beta. Although similar in many respects, the transcriptional properties of both receptors are different. In this review, we will focus on the measurement of ER-alpha only, since virtually all publications that provided evidence for guideline recommendation relate to measurement of this isoform. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Estrogen receptor beta: a second ER isoform'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link&amp;anchor=H2#H2\">",
"     \"Molecular biology and physiology of estrogen action\", section on 'Estrogen receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The responsiveness of a tumor to endocrine therapy is an important parameter in breast cancer management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particularly in the setting of metastatic breast cancer, endocrine therapy offers several advantages over conventional cytotoxic chemotherapy. Among women with newly diagnosed metastatic disease, approximately 30 to 40 percent will have an objective response to endocrine therapy, sometimes lasting for several years, and a substantial number will have a clinically significant period of disease stability (ie, neither disease progression nor regression) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. Although objective response rates are higher with first-line chemotherapy (50 to 60 percent) and responses are generally more durable, treatment-related toxicity is generally greater. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link&amp;anchor=H13#H13\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\", section on 'Endocrine therapy versus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, not all patients with breast cancer benefit from endocrine therapy. Tumor expression of ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PR can best identify those women who are most likely to benefit from endocrine therapy. Tumors that are negative for ER and PR are unlikely to respond to endocrine therapy and are better served by cytotoxic chemotherapy. Largely due to their predictive value, measurement of these receptors has become a routine part of the evaluation of breast cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link&amp;anchor=H7#H7\">",
"     \"Measurement of prognostic factors in breast cancer\", section on 'Hormone receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315310\">",
"    <span class=\"h3\">",
"     Contribution of PR expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The independent contribution of PR expression has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/11\">",
"     11",
"    </a>",
"    ]. Initial reports, which have been validated through the years, indicated that patients with ER-positive but PR-negative breast cancers have a worse prognosis than do those with ER-positive and PR-positive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1315480\">",
"     'Prognostic value of hormone receptor expression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the predictive value of PR expression remains controversial, as evidenced by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early suggestion that absent PR expression would serve to further refine the",
"      <strong>",
"       predictive",
"      </strong>",
"      utility of ER expression for benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or aromatase inhibitors has not been borne out [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. There is persistent controversy on this point, however [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, for individuals with ER-negative tumors, the observation that the gene encoding for PR is estrogen-dependent led to the hypothesis that PR expression might serve as an indication of an intact estrogen-ER-estrogen response pathway, and therefore, responsiveness to endocrine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/18\">",
"       18",
"      </a>",
"      ]. Although some studies suggest that the predictive value of PR is less important clinically as compared to ER [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/19-22\">",
"       19-22",
"      </a>",
"      ], others have shown that PR status provides additional predictive value independent of ER values [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/23-25\">",
"       23-25",
"      </a>",
"      ], especially among premenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/9,26\">",
"       9,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Like ER, PR was initially measured by forms of a ligand binding assay (LBA), and most of the data underlying our knowledge of the relationship between PR expression and response to endocrine therapy were generated using this assay. Like ER, PR is now measured almost exclusively by immunohistochemistry (IHC). There are some published reports that IHC for ER may be more predictive than LBA in identifying patients who will derive benefit from endocrine therapy, but there are no data addressing this issue for PR. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antibody-based assays (IHC)'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    In addition, as with ER, PR protein exists as two receptor isoforms (in this case, called A and B) but these forms are the products of the same gene. These isoforms of PR (A is a slightly truncated form of B) bind with one another to create homo- and heterodimers. There has been little work on the relative significance of these isoforms in clinical tissue specimens and their relevance to clinical decision making, although this is an active area of research.",
"   </p>",
"   <p>",
"    Despite these issues, PR positivity",
"    <strong>",
"     may",
"    </strong>",
"    be helpful in selecting patients with ER-negative breast cancer who might benefit from endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     ER-negative/PR-positive",
"    </span>",
"    tumors are uncommon, but endocrine therapy is usually recommended in this setting, in order to avoid undertreatment with such a highly effective and relatively low toxicity treatment strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/16\">",
"     16",
"    </a>",
"    ]. In this situation it is believed that the ER may be falsely negative.",
"   </p>",
"   <p>",
"    On the other hand, lack of PR expression should not contribute to decision making regarding endocrine treatment in women with ER-positive breast cancer.",
"   </p>",
"   <p>",
"    Guidelines from ASCO and the CAP recommend that both ER and PR analysis should be performed routinely in all invasive breast cancers, and the information used to select patients for endocrine therapy since there is evidence of potential benefit of PR testing to predict response of ER-negative, PR positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315480\">",
"    <span class=\"h3\">",
"     Prognostic value of hormone receptor expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the predictive value of hormone receptor expression is well accepted, its prognostic importance has been a matter of debate for many years.",
"   </p>",
"   <p>",
"    Women with stage I ER-positive breast cancer who receive no systemic therapy after surgery have a 5 to 10 percent lower likelihood of recurrence at five years than do those who have ER-negative tumors (",
"    <a class=\"graphic graphic_table graphicRef69786 \" href=\"UTD.htm?12/28/12749\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. However, as the length of follow-up increases, the advantage of ER-positivity in terms of relapse and death grows smaller and ultimately disappears [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. This might reflect sequential improvements in adjuvant chemotherapy (which disproportionately benefits those with hormone receptor-negative tumors) over time.",
"   </p>",
"   <p>",
"    Expression of hormone receptors is associated with a number of other well-established prognostic indicators, but not with nodal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, ER and PR status may be better markers of growth rate than of metastatic potential.",
"   </p>",
"   <p>",
"    ER-positive tumors are more likely to be histologically well differentiated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/37-39\">",
"     37-39",
"    </a>",
"    ], to have a lower fraction of dividing cells, and to be diploid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/40\">",
"     40",
"    </a>",
"    ]. They are also less likely to be associated with mutations, loss, or amplification of breast cancer-related genes such as p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], HER2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], or HER1 (the epidermal growth factor receptor [EGFR]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], all of which have been associated with a poorer prognosis. Despite these associations, there is no consistent evidence that these factors influence response to endocrine therapy in patients with receptor-positive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link&amp;anchor=H26#H26\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Response to endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormone receptor status is also associated with specific site(s) of metastatic spread. For unclear reasons, ER-positive tumors are more likely to develop clinically apparent metastases in bone, soft tissue, or the",
"    <span class=\"nowrap\">",
"     reproductive/genital",
"    </span>",
"    tracts; in contrast, ER-negative tumors more commonly metastasize to brain and liver, sites that are associated with shorter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSAYS FOR ER AND PR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally, ER and PR quantitation was done by an assay involving the competitive binding of a radiolabeled steroid ligand to the receptor. Since the early 1990's, such methods have largely been replaced by immunohistochemical (IHC) methods that rely upon the recognition of the receptor protein through the use of specific antibodies. In both cases, the receptor protein is either directly or indirectly measured. A third newer technique is measurement of ER messenger RNA by either northern blot analysis or reverse transcriptase polymerase chain reaction (RT-PCR), often as part of a multigene assay method (eg, Oncotype DX, Mammaprint) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. At present, these techniques are not recommended to replace traditional assays. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ligand binding assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prototype method for the ligand binding assay (LBA) is the dextran-coated charcoal (DCC) assay. Radiolabeled steroid ligand ([125I]-estradiol for ER, [3H]-progestin for PR) is first added to the supernatant of homogenized tissue (representing the cytosol) and incubated to allow labeled steroid to bind all available receptor protein [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/52\">",
"     52",
"    </a>",
"    ]. DCC, which absorbs unbound steroid, is added, after which the charcoal with adherent unbound steroid is separated by centrifugation.",
"   </p>",
"   <p>",
"    Since the receptor-bound portion remains in the supernatant and the free fraction is found in the charcoal precipitate, the bound and unbound fractions can then be quantified for a range of concentrations of radiolabeled steroid and the results used to create a multipoint Scatchard plot. From this Scatchard plot, the total concentration of receptor protein in the cytosol is obtained and is usually expressed as femtomoles of receptor protein per mg of total cytosol protein",
"    <span class=\"nowrap\">",
"     (fmol/mg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibody-based assays (IHC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of monoclonal antibodies to the ER in the 1980&rsquo;s had a profound and long lasting impact on the methodologies for ER assay. Initially, quantification was by enzyme immunoassay (EIA) that still required preparation of cytosols from homogenates of fresh tissue but was more precise and far less laborious than the DCC assay. The results from the new structurally-specific assay were highly correlated with the old functionally-specific assay, and cut-offs approved by the US Food and Drug Administration (FDA) for EIA (ER positivity &ge;15",
"    <span class=\"nowrap\">",
"     fmol/mg",
"    </span>",
"    cytosol protein) were mostly based upon correlative values with LBA (ER positivity &ge;10",
"    <span class=\"nowrap\">",
"     fmol/mg",
"    </span>",
"    cytosol protein). In addition, use of an optimal cutting temperature (OCT) embedding compound with frozen breast tumors did not alter either ER or PR results.",
"   </p>",
"   <p>",
"    IHC application of hormone receptor-specific antibodies was initially successful only on sections of frozen tissue, but antigen retrieval methods developed in the early 1990&rsquo;s and new antibodies allowed their application to formalin-fixed and paraffin-embedded material. The ease of this approach, coupled with the availability of inexpensive reagents that were applicable to routine pathology specimens and the ability to evaluate small cancers and ensure that only invasive tumor cells are assessed, has led to IHC becoming the near universal choice for ER and PR assay determinations since the early 1990s.",
"   </p>",
"   <p>",
"    However, much of the data that provided the basis for our knowledge of the relationship between the presence of significant amounts of ER and response to endocrine therapy were derived using the LBA, and positive-negative cut-offs were developed by reference to LBA results. IHC methods have been subject to retrospective comparisons with established methods such as LBA, and there are some published reports indicating that IHC may be more predictive than LBAs in identifying patients who will derive benefit from endocrine therapy (",
"    <a class=\"graphic graphic_table graphicRef56559 \" href=\"UTD.htm?0/11/189\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/6-10,19,24,53-57\">",
"     6-10,19,24,53-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IHC assays that identify ER as a nuclear protein in cell fractionation experiments largely support this observation. Signaling through this mechanism is designated the &ldquo;genomic&rdquo; signaling pathway. However, more recent laboratory studies using cultured human breast cancer cell lines have shown that ER may signal through a separate, &ldquo;non-genomic&rdquo; pathway. In this case, ER has been found to be associated with the breast cancer cell membrane and its effect is mediated through a cascade of tyrosine kinases and phosphatases, ultimately resulting in gene activation through nuclear transcription factor modulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link&amp;anchor=H4#H4\">",
"     \"Molecular biology and physiology of estrogen action\", section on 'Nongenomic actions of estrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IHC can be performed on thin sections of formalin-fixed, paraffin-embedded tissue, or on sectioned frozen specimens. Initially, 4 to 5 micron sections are cut and mounted on protein-coated glass slides. Sections are heated to uncover hidden protein epitopes and exposed to a primary anti-ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-PR antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/58\">",
"     58",
"    </a>",
"    ]. A secondary antibody that recognizes the first, which is attached to an enzyme such as horseradish peroxidase, is then added. This linked enzyme converts substrates like diaminobenzidine into colored molecules upon exposure to a developer. Tissue sections are then counterstained, and the amount of ER or PR protein present is semiquantitated according to the presence of nuclear staining, which may be heterogeneous in malignant epithelium (",
"    <a class=\"graphic graphic_picture graphicRef63384 \" href=\"UTD.htm?18/39/19065\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Staining of membranes or cytoplasm may be seen as valid staining, but should",
"    <strong>",
"     not",
"    </strong>",
"    be used to define ER or PR positivity. If such staining is seen in both the tumor and the internal control (normal ducts in the specimen), the assay should be repeated because it is likely that the staining is spurious.",
"   </p>",
"   <p>",
"    IHC offers several advantages over LBA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can be performed on a variety of samples including fine needle aspirates, core biopsies, small tumors, cell blocks from body fluids such as pleural effusions, frozen tissue, or fixed, paraffin-embedded archival tissue.",
"     </li>",
"     <li>",
"      In contrast to the LBA, total receptor protein is measured, not just the unbound fraction. As a result, IHC is not affected by endogenous or exogenous steroids or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      It is simple to perform and does not require specialized equipment",
"     </li>",
"     <li>",
"      As noted above, in some reports, the ability to discriminate estrogen-responsive from estrogen-nonresponsive tumors is somewhat better with IHC than with LBAs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/6-8,19\">",
"       6-8,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these reasons, IHC has rapidly become the predominant method for measuring ER and PR in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321780\">",
"    <span class=\"h3\">",
"     Assay variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;IHC provides two pieces of information: the percentage of positive cells and the intensity of staining within individual cells. Scoring systems (ie, percentage of positive cells versus staining intensity) as well as cutoff points (thresholds) separating positive and negative samples differ among individual laboratories. Some (including a consensus development panel of the NIH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/61\">",
"     61",
"    </a>",
"    ]) regard any demonstrable staining as positive, while others use a minimum of 10 or even 20 percent nuclear staining to denote a positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/20,62,63\">",
"     20,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported percentages of positive cells vary according to the method by which the observations are made. Some observers quantitate by overall assessment, some manual count areas of positivity, and others use image analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In contrast to the significant body of data correlating the degree of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    benefit in ER-positive tumors to quantitative ER levels as assessed by LBA (including levels as low as 10",
"    <span class=\"nowrap\">",
"     fmol/mg",
"    </span>",
"    of cytosolic protein [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/22\">",
"     22",
"    </a>",
"    ]), the importance of quantifying hormone receptor expression by IHC remains an open question. In the Stockholm Breast Cancer Study Group report, for example, the degree of tamoxifen benefit in ER-positive tumors correlated with ER levels by LBA but not with the percentage of cells stained ER-positive by IHC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/57\">",
"     57",
"    </a>",
"    ]. Reproducible quantitation of IHC results by computer-aided image analysis will likely be valuable in this regard, providing a more accurate classification of ER-positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/66-72\">",
"     66-72",
"    </a>",
"    ]. However, none of these methods are in common use, although at least one is commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/73\">",
"     73",
"    </a>",
"    ]. Use of image analysis has suffered because of lack of published recommendations for equipment validation and testing requirements. Methods are currently highly variable for these reasons.",
"   </p>",
"   <p>",
"    Recent reports have highlighted the extent of variability in ER and PR assay results caused by a variety of factors. Results can vary substantially between laboratories because of differences in specimen handling, tissue fixation, antigen retrieval, and antibody type. Depending on the epitope recognized, different antibodies may only detect certain forms of the receptor, such as ER-alpha or ER-beta, and may fail to detect a specific form or variant. In addition, interpretation of assay results is variable due to the variable threshold values for positive and negative [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/10,64,74-76\">",
"     10,64,74-76",
"    </a>",
"    ]. These variations have resulted in serious issues with ER reliability prior to the development of a national guideline. (See",
"    <a class=\"local\" href=\"#H12694047\">",
"     'Guideline recommendations to improve ER and PR testing accuracy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The situation is especially problematic in Canada. Canada has a provincial-based health care system in which each province develops its own method of assuring health care quality measures. This results in significant variation in policies and practices among the provinces:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An inquiry into ER testing practices in Newfoundland revealed that about a third of 1023 ER tests on patients in that Canadian Province tested between 1997 and 2005 were scored falsely negative when retested in a central lab in Ontario [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/77\">",
"       77",
"      </a>",
"      ]. More than 100 of these patients have since died, and a class action law suit has commenced, claiming negligence in ER testing, and therefore harm due to failure to provide adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The inquiry revealed that problems in hormone receptor testing",
"      <strong>",
"      </strong>",
"      occurred because of turnover and lack of relevant training of pathologists and technologists doing the testing, lack of appropriate quality assurance methods, inadequate quality control policies and practices, and poor communication and teamwork among the healthcare professionals. In fact, all ER cases that were identified as falsely negative were found to have one or more of three characteristics: poor fixation, negative internal control (ie, when normal duct epithelium was present, it was IHC-negative), or absent internal controls.",
"     </li>",
"     <li>",
"      A similar problem has also come to light in Quebec, where health care quality policies for anatomic pathology laboratory testing are defined on a hospital-by-hospital basis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar assay testing issues have been highlighted in other parts of the world. As an example, older reports of breast cancer from sites in Asia reported that breast cancer in Asian women was mostly ER negative. However, the percentage of ER positive tumors in a series of 1000 patients from the Philippines was 68.9 percent after changes in fixation were instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/79\">",
"     79",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In other series from Vietnam and China [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/80\">",
"     80",
"    </a>",
"    ], and Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/81\">",
"     81",
"    </a>",
"    ], over two-thirds of patients had exhibited ER and PR-positive disease after implementation of standardized practices for procurement and formalin fixation of breast cancer specimens for hormone receptor assays.",
"   </p>",
"   <p>",
"    Reports from large multinational cooperative groups have addressed concordance between ER testing at the primary institutional site of patient enrollment and centrally by high volume, academic laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/9,20,82\">",
"     9,20,82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In The Breast Cancer Intergroup trial ECOG 2197, 11 percent of local ER-negative tests were scored positive upon central testing, for an overall concordance rate for ER of approximately 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ER and PR assay differences between local versus central reference laboratory testing were addressed in a study examining tumor blocks from almost 5000 patients enrolled from countries worldwide (except US and China) in the ongoing Adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      Treatment Optimization (ALTTO) trial between June 2007 and November 2008 that were submitted for prerandomization confirmation of HER2 status at the European Institute of Oncology (EIO) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/9\">",
"       9",
"      </a>",
"      ]. Overall, 4.3 percent of the cases were found to be falsely positive for ER on central review, and 20 percent of cases were found to be falsely negative.",
"     </li>",
"     <li>",
"      Viale et al examined the prognostic and predictive value of both local and central hormone receptor expression on disease-free survival (DFS) for 3650 patients who had been assigned to the single-agent arms in the BIG 1-98 adjuvant trial testing evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      versus combined therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/20\">",
"       20",
"      </a>",
"      ]. Using positivity criteria of ER",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PR &ge;10 percent of positive cells, central review confirmed 97 percent of tumors as were hormone receptor-positive. However, 69 percent of the small number of tumors (n =105) said to be ER-negative were actually ER-positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these cited trials suffer from differences in methodology and thresholds between central and local institutional testing, which make it difficult to accurately quantify the magnitude of the difference between local versus central laboratory testing. In general, the ER false-negative rate (central versus local testing) was in the range of 10 percent while the false-positive rate has been as high as 5 percent for ER. Having a guideline available that specifies the threshold for positive and negative assays will likely mitigate these accuracy concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694047\">",
"    <span class=\"h1\">",
"     GUIDELINE RECOMMENDATIONS TO IMPROVE ER AND PR TESTING ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guideline panel convened by ASCO and CAP reviewed the literature concerning ER and PR testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The data set, which included 216 studies assessing IHC methods related to a comparator (which in 17 studies was patient outcomes, such as disease-free survival) was the basis for the recommendations.",
"   </p>",
"   <p>",
"    Guideline elements that were recommended to reduce assay variability included definition of appropriate specimen handling, fixation, and analytical testing methods, thresholds for interpretation of positive and negative results, quality assurance methods, and monitoring strategies for individual laboratories. These elements are described in the following sections and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef65263 \" href=\"UTD.htm?20/22/20845\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694061\">",
"    <span class=\"h2\">",
"     Specimen handling methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694069\">",
"    <span class=\"h3\">",
"     Cold ischemic time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to testing variation begin as soon as the breast tissue is removed from the patient. Both the warm and cold ischemic times are widely accepted as important variables in the analysis of labile macromolecules (eg, proteins, RNA, DNA) from clinical tissue samples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Warm ischemia time is the time from the interruption of the blood supply to the tumor by the surgeon to the excision of the tissue specimen.",
"     </li>",
"     <li>",
"      Cold ischemia time is the time from specimen excision to the initiation of tissue fixation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous studies have documented the progressive loss of activity of labile macromolecules following the surgical interruption of blood flow, which leads to tissue ischemia, acidosis and enzymatic degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The contribution of the warm ischemic interval to this macromolecular degradation is under study. &nbsp;",
"   </p>",
"   <p>",
"    Breast resection specimens should be fixed as quickly as possible in an adequate volume of fixative (optimally 10-fold greater than volume of the specimen). The time of tissue collection (defined as the time that the tissue is handed from the surgical field) and the time the tissue is placed in fixative should be recorded in order to document the time to fixation.",
"   </p>",
"   <p>",
"    Every effort should be made to transport specimens from the operating room to the pathology laboratory as soon as possible. Ideally, the time from tumor removal to fixation should be kept to one hour or less",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This recommendation conflicts with the 2007",
"    <span class=\"nowrap\">",
"     ASCO/CAP",
"    </span>",
"    recommendation for HER2 testing, which recommended that cold ischemia times be as short as possible. An ASCO Clinical Notice reconciling the two guidelines suggested that the",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    testing recommendations be followed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link&amp;anchor=H7#H7\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Recommendations of the ASCO/CAP consensus panel'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    After being received in the pathology laboratory, specimens should be oriented and carefully inked for surgical margin assessment, sectioned at 5 mm intervals and placed in 10 percent neutral (phosphate) buffered formalin (NBF). If the excision specimen was obtained remotely from the grossing laboratory, the sample should be bisected through the tumor and promptly placed in NBF prior to transport. The time of removal of the tumor from the patient and the time to insertion of tumor sample into fixative should be noted by the remote operating suite personnel.",
"   </p>",
"   <p>",
"    Studies have examined the effect of delays in tissue processing on ER negativity rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/87\">",
"     87",
"    </a>",
"    ]. In this retrospective multicenter study of 5000 patients treated within the Intermountain Healthcare hospital system, all analytical and reporting considerations were done in a single location. The rates of ER negativity were significant different and varied with both the site of tumor removal and the days on which surgery was performed. For patients having tumor resections on Monday through Thursday at any site, rates of ER negativity were significantly lower than for those who had surgery on Friday or Saturday. This strongly suggested that specimen handling issues (in particular, prolonged specimen handling, (",
"    <a class=\"graphic graphic_figure graphicRef76536 \" href=\"UTD.htm?34/47/35581\">",
"     figure 1",
"    </a>",
"    )) were at fault. &nbsp;",
"   </p>",
"   <p>",
"    Intermountain Healthcare conducted a followup study where times of tissue removal and time to fixation (cold ischemic time) were standardized and recorded by two of the six sites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/88\">",
"     88",
"    </a>",
"    ]. For the two sites, the average time to fixative was 18 minutes, and the average time in fixative was 18 hours. In this cohort, there was a lower prevalence of ER and PR negativity as compared to the four facilities that lacked standardized preanalytical specimen handling conditions, although only the difference in PR negativity rate (24 versus 30 percent) was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694167\">",
"    <span class=\"h3\">",
"     Fixative type and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only 10 percent NBF should be used as the fixative for breast tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. If a laboratory uses a formalin alternative for fixation, the assay must first be validated against NBF fixation.",
"   </p>",
"   <p>",
"    Breast tissue specimens (including core needle biopsies) must be fixed in 10 percent NBF for no less than six hours and not more than 72 hours before processing. A later ASCO Guidelines Clinical Notice reconciling the combined",
"    <span class=\"nowrap\">",
"     ASCO/CAP",
"    </span>",
"    recommendations for HER2 and",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    testing recommended that fixation times be limited to no more than 48 hours for both tests if they are performed on the same tissue specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link&amp;anchor=H7#H7\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Recommendations of the ASCO/CAP consensus panel'",
"    </a>",
"    .) Formalin is aqueous, completely dissolved formaldehyde. Formalin penetrates tissue at a rate of approximately 1",
"    <span class=\"nowrap\">",
"     mm/hour,",
"    </span>",
"    which is the reason why breast excision samples must be incised in a timely fashion to initiate formalin fixation throughout the tissue. Fixation does not begin until formaldehyde has penetrated into the tissue. However, permeation of tissue by formalin is not the same as the chemical reaction of fixation, which involves protein cross-linking by formaldehyde. Underfixation of breast tissue may lead to false-negative ER results. Overfixation is likely to be less problematic than underfixation, but could also potentially lead to false negative results due to excessive protein cross-linking by formaldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/89,91\">",
"     89,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694226\">",
"    <span class=\"h3\">",
"     Analysis of ER and PR expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for ER and PR by IHC must be performed using antibodies that have proven reliable in predicting patient outcome of endocrine treatment. A list of antibodies with acceptable clinical validation was provided in the guideline document [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], but any antibody that has been shown to predict endocrine therapy responses in published reports can be used for these assays.",
"   </p>",
"   <p>",
"    Testing for ER and PR must be validated by each laboratory in a set of samples (40 to 80) that are compared with those of another laboratory using the same antibody method and threshold value for interpretation. Concordance of the results must be 95 percent for positive samples and 90 percent for ER or PR negative samples before the laboratory can begin performing the testing on patient samples. The testing method must also involve both positive and negative assay controls that are run concurrent with every clinical specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694235\">",
"    <span class=\"h2\">",
"     Interpretation of ER and PR tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER and PR tests should only be evaluated by a pathologist after assuring that the test has been done properly. This is done by reviewing the status of the external controls and also reviewing the status of internal controls for each breast cancer sample. Normal breast epithelium is usually ER and PR positive with at least 10 percent of cells expressing these receptors.",
"   </p>",
"   <p>",
"    Review of internal controls is critical for proper interpretation because it assures that if present, the ER and PR receptors can be correctly identified in the tissue being examined. The entire sample of tumor cells is then carefully examined and the percent of tumor cells expressing ER or PR receptor in the nuclei of the cells is recorded along with an assessment of the strength of the receptor staining (weak, moderate, strong, 1-3+).",
"   </p>",
"   <p>",
"    When IHC assays replaced LBAs in the early-to-mid 1990s, relatively few clinical studies had been performed to establish optimum cut points for either assay. Instead, most studies simply compared the two and assumed that the IHC level which corresponded to the previously determined LBA cut point was also valid (",
"    <a class=\"graphic graphic_table graphicRef56559 \" href=\"UTD.htm?0/11/189\">",
"     table 2",
"    </a>",
"    ). IHC appears to be equivalent or superior to LBA in predicting response to endocrine therapy. IHC testing results of &gt;1 percent positive-staining carcinoma cells (for either ER or PR) are associated with significant clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/6,9,23,24,92,93\">",
"     6,9,23,24,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies describe the relationship between hormone receptor levels as determined by IHC and patient outcomes. Overall survival, disease-free survival,",
"    <span class=\"nowrap\">",
"     recurrence/relapse-free",
"    </span>",
"    survival, five-year survival, time to treatment failure, response to endocrine therapy, and time to recurrence were all positively associated with ER levels; overall survival, time to treatment",
"    <span class=\"nowrap\">",
"     failure/progression,",
"    </span>",
"    response to endocrine therapy, and time to recurrence have all been positively related to PR levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/6,17,94\">",
"     6,17,94",
"    </a>",
"    ]. These studies suggest that patients with higher hormone receptor levels will have a higher probability of positive outcomes and may influence oncologists&rsquo; and patients&rsquo; treatment decisions.",
"   </p>",
"   <p>",
"    The threshold for a positive result was carefully considered by the guideline panel [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Given the substantial impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and other endocrine therapies on mortality reduction and its relatively low toxicity profile, the panel recommended that the cutoff to distinguish \"positive\" from \"negative\" cases should be &gt;1 percent ER-positive tumor cells.",
"    <strong>",
"    </strong>",
"    They recognized that this lower threshold may result in increased application of endocrine therapies. Breast oncologists have the option to make treatment recommendations for endocrine therapy in light of patient preferences and circumstances.",
"   </p>",
"   <p>",
"    As noted above, although some studies suggest the predictive role of PR may not be as important clinically as ER, others have shown that PR status provides additional predictive value independent of ER values, especially among premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/21,23,25\">",
"     21,23,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1315310\">",
"     'Contribution of PR expression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The panel recommended that PR be measured on all samples and that the same threshold for positivity be applied [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1315310\">",
"     'Contribution of PR expression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694341\">",
"    <span class=\"h2\">",
"     Reporting results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reporting elements that should be included are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78069 \" href=\"UTD.htm?2/29/2525\">",
"     table 4",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    The percentage of tumor cells, intensity of tumor cell staining, and the interpretation of the test as positive or negative should be provided. Tumors exhibiting less than 1 percent of tumor cells staining for ER or PR of any intensity should be considered negative based upon data that such patients do not derive meaningful benefit from endocrine therapy.",
"   </p>",
"   <p>",
"    The sample should only be considered negative in the presence of appropriately stained extrinsic and intrinsic controls (see below). Any specimen lacking intrinsic elements (normal breast epithelium) that is negative by ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PR IHC assay should have the assay repeated using another tumor block or another tumor specimen, and reported as uninterpretable rather than as negative. The pathologist must always take specimen handling issues into consideration and correlate the results of the ER and PR assay with the histologic appearance of the tumor (eg, almost all grade 1 [low grade] breast cancers are ER and PR positive). Results that conflict with clinical considerations should be discussed and perhaps repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12694355\">",
"    <span class=\"h2\">",
"     Laboratory quality assurance monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guideline is based on regulatory requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88), as well as published studies, of the experience of CAP and other groups, and expert panel consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/74,95-97\">",
"     74,95-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ER and PR testing should be performed in a CAP-accredited laboratory or in a laboratory that meets the additional accreditation requirements as set out within the guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While mandatory proficiency testing has been a component of laboratory accreditation in Australia and New Zealand since 2001, there are no regulatory requirements for proficiency testing of ER or PR assays in the US in order for laboratories to be accredited by CLIA. However, the current guideline makes successful performance in proficiency testing mandatory for accreditation. The CAP Laboratory Accreditation Program will monitor performance in the required proficiency testing. Competency of the laboratory personnel performing the",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    testing, including the pathologists, is an important aspect of the laboratory proficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assay for tumor expression of estrogen receptor (ER) and progesterone receptor (PR) have established utility in the clinical management of patients with both early stage and advanced breast cancer, and they should be routinely obtained on all tumor specimens. Receptor positivity is an important indicator of hormone responsiveness and identifies tumors for which endocrine therapy is a valuable therapeutic option, both for adjuvant therapy and for advanced disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunohistochemistry (IHC) has rapidly become the predominant method for measuring ER and PR in clinical practice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antibody-based assays (IHC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      However, reports have highlighted the extent of variability in ER and PR IHC assay caused by a variety of factors including differences in specimen handling, tissue fixation, antigen retrieval, and antibody type. In addition, variability in interpretation of assay results is caused by variable threshold values for positive and negative. These variations have resulted in serious issues with ER reliability prior to the development of a national guideline. (See",
"      <a class=\"local\" href=\"#H1321780\">",
"       'Assay variability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New guidelines are available from a joint panel of the American Society of Clinica Oncology and the College of American Pathologists that provide recommendations to improve test accuracy (",
"      <a class=\"graphic graphic_table graphicRef65263 \" href=\"UTD.htm?20/22/20845\">",
"       table 3",
"      </a>",
"      ) and recommendations for reporting of results (",
"      <a class=\"graphic graphic_table graphicRef78069 \" href=\"UTD.htm?2/29/2525\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/47/19194/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12694047\">",
"       'Guideline recommendations to improve ER and PR testing accuracy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These guidelines, along with strategies to monitor compliance with them should improve the accuracy of these assays, and therefore, improve the selection of patients for whom endocrine therapy is likely to provide clinical benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/1\">",
"      Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/2\">",
"      Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/3\">",
"      Bezwoda WR, Esser JD, Dansey R, et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991; 68:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/4\">",
"      Manni A, Arafah B, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980; 46:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/5\">",
"      McClelland RA, Berger U, Miller LS, et al. Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 1986; 46:4241s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/6\">",
"      Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/7\">",
"      Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996; 78:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/8\">",
"      Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/9\">",
"      Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 2006; 98:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/10\">",
"      Thomson CS, Twelves CJ, Mallon EA, et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast 2002; 11:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/11\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/12\">",
"      Clark GM, McGuire WL, Hubay CA, et al. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983; 309:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/13\">",
"      Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011; 16:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/14\">",
"      Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/15\">",
"      Osborne CK, McGuire WL. Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med 1979; 130:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/16\">",
"      Hayes DF. Markers of endocrine sensitivity. Breast Cancer Res 2008; 10 Suppl 4:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/17\">",
"      Bartlett JM, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011; 29:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/18\">",
"      Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/19\">",
"      Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/20\">",
"      Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/21\">",
"      Jalava P, Kuopio T, Huovinen R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 2005; 25:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/22\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/23\">",
"      Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/24\">",
"      Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 2006; 13:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/25\">",
"      Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 2004; 11:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/26\">",
"      Stendahl M, Ryd&eacute;n L, Nordenskj&ouml;ld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006; 12:4614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/27\">",
"      Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/28\">",
"      Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/29\">",
"      Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005; 103:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/30\">",
"      Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982; 2:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/31\">",
"      McGuire WL, Tandon AK, Allred DC, et al. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/32\">",
"      Adami HO, Graffman S, Lindgren A, S&auml;llstr&ouml;m J. Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 1985; 5:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/33\">",
"      Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/34\">",
"      Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997; 76:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/35\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/36\">",
"      Arisio R, Sapino A, Cassoni P, et al. What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas? J Clin Pathol 2000; 53:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/37\">",
"      Ferrero-Po&uuml;s M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 2001; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/38\">",
"      Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001; 92:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/39\">",
"      Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/40\">",
"      Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993; 28:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/41\">",
"      Falette N, Paperin MP, Treilleux I, et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998; 58:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/42\">",
"      Elledge RM, Fuqua SA, Clark GM, et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/43\">",
"      Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/44\">",
"      Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/45\">",
"      Ferrero-Po&uuml;s M, Hac&egrave;ne K, Bouchet C, et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6:4745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/46\">",
"      Bolla M, Chedin M, Souvignet C, et al. Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors. Breast Cancer Res Treat 1990; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/47\">",
"      Pawlowski V, R&eacute;villion F, Hebbar M, et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6:4217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/48\">",
"      Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/49\">",
"      Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004; 164:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/50\">",
"      Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/51\">",
"      Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/52\">",
"      McGuire WL, De La Garza M, Chamness GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 1977; 37:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/53\">",
"      Andersen J, Thorpe SM, Rose C, et al. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncol 1991; 30:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/54\">",
"      Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997; 45:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/55\">",
"      Zafrani B, Aubriot MH, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000; 37:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/56\">",
"      McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/57\">",
"      Khoshnoud MR, L&ouml;fdahl B, Fohlin H, et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat 2011; 126:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/58\">",
"      Taylor CR, Shi SR, Chaiwun B, et al. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 1994; 25:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/59\">",
"      King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984; 307:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/60\">",
"      Layfield LJ, Saria E, Mooney EE, et al. Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol 1998; 110:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/61\">",
"      Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/62\">",
"      Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/63\">",
"      Regitnig P, Reiner A, Dinges HP, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002; 441:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/64\">",
"      Layfield LJ, Gupta D, Mooney EE. Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Methods. Breast J 2000; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/65\">",
"      Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 2004; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/66\">",
"      Esteban JM, Ahn C, Mehta P, Battifora H. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994; 102:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/67\">",
"      McClelland RA, Finlay P, Walker KJ, et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990; 50:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/68\">",
"      Bejar J, Sabo E, Misselevich I, et al. Comparative study of computer-assisted image analysis and light-microscopically determined estrogen receptor status of breast carcinomas. Arch Pathol Lab Med 1998; 122:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/69\">",
"      Bacus S, Flowers JL, Press MF, et al. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988; 90:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/70\">",
"      Gokhale S, Rosen D, Sneige N, et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 2007; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/71\">",
"      Turbin DA, Leung S, Cheang MC, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 2008; 110:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/72\">",
"      Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011; 29:2978.",
"     </a>",
"    </li>",
"    <li>",
"     Automated quantitiative immunofluorescence assay (AQUA) for ER, PR, and HER2 available from HistoRx, Branford CT.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/74\">",
"      Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001; 115:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/75\">",
"      Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol 2004; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/76\">",
"      Biesterfeld S, Veuskens U, Schmitz FJ, et al. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer. Anticancer Res 1996; 16:2497.",
"     </a>",
"    </li>",
"    <li>",
"     www.gov.nl.ca/releases/2009/health/CameronInquiry.pdf.",
"    </li>",
"    <li>",
"     Seguin R. Breast cancer patients to be retested in Quebec. Breast cancer patients to be retested in Quebec; Toronto, 6/22/2009.",
"    </li>",
"    <li>",
"     Uy GB, Laudico AV, Fernandez AM, et al. Immuno-histochemical assay of hormone receptors in breast cancer at the Philippine General Hospital:  Importance of early fixation of specimens. Philip J Surg Spec 2007; 62:123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/80\">",
"      Nichols HB, Trentham-Dietz A, Love RR, et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/81\">",
"      Adebamowo CA, Famooto A, Ogundiran TO, et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008; 110:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/82\">",
"      Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/83\">",
"      Gown AM. Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol 2004; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/84\">",
"      Nenci I, Beccati MD, Piffanelli A, Lanza G. Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. J Steroid Biochem 1976; 7:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/85\">",
"      Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005; 12:10.",
"     </a>",
"    </li>",
"    <li>",
"     ASCO Guidelines Clinical Notice on reconciliation of HEr2 and ER/PR testing recommendations available online at file://www.asco.org/ASCO/Downloads/Cancer%20Policy%20and%20Clinical%20Affairs/Clinical%20Affairs%20(derivative%20products)/HER%202/HER%202%20Clinical%20Notice%201.13.11.pdf (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/87\">",
"      Nkoy FL, Hammond ME, Rees W, et al. Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study. Arch Pathol Lab Med 2010; 134:606.",
"     </a>",
"    </li>",
"    <li>",
"     Hammond ME, Fetzer J, Belnap T, et al. Impact of Recording of Pre-Analytical Specimen Handling Conditions for ER and PR Testing in Women with Breast Cancer, San Antonio Breast Cancer Symposium, 2009 Abstract 4154.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/89\">",
"      Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003; 120:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/90\">",
"      Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 2008; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/91\">",
"      Arber DA. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 2002; 10:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/92\">",
"      Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006; 24:5637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/93\">",
"      Phillips T, Murray G, Wakamiya K, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 2007; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/94\">",
"      Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990; 66:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/95\">",
"      Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/96\">",
"      Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/47/19194/abstract/97\">",
"      Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol 2007; 60:1277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 747 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-B40BC8A1ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19194=[""].join("\n");
var outline_f18_47_19194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTROGEN AND PROGESTERONE RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1315310\">",
"      - Contribution of PR expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1315480\">",
"      - Prognostic value of hormone receptor expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSAYS FOR ER AND PR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ligand binding assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibody-based assays (IHC)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1321780\">",
"      - Assay variability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12694047\">",
"      GUIDELINE RECOMMENDATIONS TO IMPROVE ER AND PR TESTING ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12694061\">",
"      Specimen handling methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12694069\">",
"      - Cold ischemic time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12694167\">",
"      - Fixative type and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12694226\">",
"      - Analysis of ER and PR expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12694235\">",
"      Interpretation of ER and PR tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12694341\">",
"      Reporting results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12694355\">",
"      Laboratory quality assurance monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/747|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/47/35581\" title=\"figure 1\">",
"      IHC data about ER neg rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/747|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/39/19065\" title=\"picture 1\">",
"      Estrogen receptor immunohistochemical staining in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/28/12749\" title=\"table 1\">",
"      Surv SEER by receptor status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/11/189\" title=\"table 2\">",
"      Comparison of ER by LBA and IHC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/22/20845\" title=\"table 3\">",
"      Recommendations for ER and PR testing by IHC in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/29/2525\" title=\"table 4\">",
"      Reporting elements for ER and PR immunohistochemistry assays",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=related_link\">",
"      Molecular biology and physiology of estrogen action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_47_19195="Cardiovascular parameters for grading TTTS severity";
var content_f18_47_19195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardiovascular parameters assessed in grading severity of twin-twin transfusion syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Donor twin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical artery blood flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recipient twin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular hypertrophy or wall thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac dilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid valve regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid valve inflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve inflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ductus venosus flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical vein flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right-sided outflow tract obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary regurgitation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rychik J, Tian Z, Bebbington M, et al. The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. Am J Obstet Gynecol 2007; 197:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19195=[""].join("\n");
var outline_f18_47_19195=null;
var title_f18_47_19196="Causes of hemarthrosis";
var content_f18_47_19196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hemarthrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Iatrogenic (traumatic arthrocentesis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. Without bone fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c. With bone fracture (lipohemarthrosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d. Post-operative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Hematological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Drug induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. Inherited hematologic disorders, ie, coagulation disorders, sickle cell disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c. Acquired hematological disorders, ie, myeloproliferative diseases, essential thrombocytosis, and thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Neurological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Charcot's joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Pigmented villonodular synovitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Hemangioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. Arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c. Aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d. Synovial vascular structural abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        6. Osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Degenerative tear of the meniscus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. Osteoarthritis (other)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        7. Crystalline diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Gout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. Pseudogout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c. Milwaukee shoulder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        8. Nutritional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. Scurvy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        9. Septic arthritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Dougados, M. Synovial fluid cell analysis. Bailliere's Clinical Rheumatology 1996; 10:519. and Baker, C. J Med Assoc Georgia 1992; 81:301.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19196=[""].join("\n");
var outline_f18_47_19196=null;
var title_f18_47_19197="Survival by histology";
var content_f18_47_19197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival of paranasal sinus cancer according to tumor site and histologic type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tumor site",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Ethmoid sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       PNS",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Characteristic",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 399)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 650)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 305)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 650)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"9\">",
"       Histology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Adenocarcinoma",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       53.8",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       47.7",
"      </td>",
"      <td>",
"       153",
"      </td>",
"      <td>",
"       43.6",
"      </td>",
"      <td>",
"       107",
"      </td>",
"      <td>",
"       44.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Esthesioneuroblastoma",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       81.7",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Adenoid cystic carcinoma",
"      </td>",
"      <td>",
"       91",
"      </td>",
"      <td>",
"       53.1",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       57.5",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       64.1",
"      </td>",
"      <td>",
"       32*",
"      </td>",
"      <td>",
"       65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Melanoma",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       25.9",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Sarcoma",
"      </td>",
"      <td>",
"       59",
"      </td>",
"      <td>",
"       48.7",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       44.8",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       18&bull;",
"      </td>",
"      <td>",
"       46.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Squamous cell carcinoma",
"      </td>",
"      <td>",
"       156",
"      </td>",
"      <td>",
"       45.2",
"      </td>",
"      <td>",
"       401",
"      </td>",
"      <td>",
"       29.2",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       18.7",
"      </td>",
"      <td>",
"       101",
"      </td>",
"      <td>",
"       43",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Undifferentiated carcinoma",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       30.5",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Mucoepidermoid carcinoma",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       61.9",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       35.9",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Other",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       35.8",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       38.7",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       32.1",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       92.3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: number of patients; NA: not available; NE: not estimated; OS: overall survival; PNS: paranasal sinuses (including maxillary, ethmoid, sphenoid, and frontal sinuses; esthesioneuroblastoma excluded).",
"     <br>",
"      * Minor salivary malignancies, including adenoid cystic carcinoma.",
"      <br>",
"       &bull; High-grade sarcomas only.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Cantu, G, et al. Arch Otolaryngol Head Neck Surg 2008; 134:170.",
"      <br>",
"       2. Bhattacharyya, N. J Oral Maxillofac Surg 2003; 61:1016.",
"       <br>",
"        3. Ganly, I, et al. Head Neck 2005; 27:575.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19197=[""].join("\n");
var outline_f18_47_19197=null;
var title_f18_47_19198="Pressure tracings pericarditis";
var content_f18_47_19198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pressure tracings in constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormal right atrial and ventricular pressure waveforms in a patient with constrictive pericarditis. Note the elevation and equalization of end-diastolic pressures, with a characteristic \"dip and plateau\" (or \"square-root sign\"). The steep Y descent reflects rapid early ventricular filling as right atrial emptying is rapid and unimpeded. The nadir of the Y descent reflects abrupt cessation of early diastolic ventricular filling. A similar pattern may be seen in cardiac tamponade or restrictive cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19198=[""].join("\n");
var outline_f18_47_19198=null;
var title_f18_47_19199="Evaluation of women for CAD";
var content_f18_47_19199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Algorithm for the evaluation of intermediate to high likelihood women with atypical or typical chest pain, dyspnea, or reduced activities of daily living",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 411px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ETT: exercise treadmill test; METs: metabolic equivalents; and LVEF: left ventricular ejection fraction.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Mieres, JH, Shaw, LJ, Hendel, RC, et al. A report of the American Society of Nuclear Cardiology Task Force on Women and Heart Disease (writing group on perfusion imaging in women). J Nucl Cardiol 2003; 10:95.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_47_19199=[""].join("\n");
var outline_f18_47_19199=null;
